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Abstract 
ATRX is a Rad54 translocase homolog implicated in regulating the epigenetic 
environment of heterochromatin, mitosis, and gene transcription. Myelin is a 
specialized membrane encompassing axons of neurons, allowing for efficient 
propagation of action potentials. CNS myelin arises via oligodendrocyte precursor 
cell (OPC) differentiation into myelinating oligodendrocytes (OLs), which then extend 
and wrap axons. Myelination is a tightly regulated process, however the 
mechanisms involved have yet to fully manifest. Here, we report that ATRX loss 
results in hypomyelination due to a defect in OPC differentiation and OL maturation, 
as ATRX loss did not affect OPC production, proliferation, or cholesterol 
biosynthesis. Additionally, myelin sheath formation was unaffected when ATRX was 
lost specifically from OLs, suggesting a non cell-autonomous role of ATRX in 
myelination. Clarifying the role of ATRX in myelination presents a novel mechanism 
that regulates myelin sheath formation, and findings from this study will benefit future 
treatments of myelin disorders, including ATR-X. 
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1 Introduction 
 
1.1 ATRX 
1.1.1 The ATRX gene and protein 
The alpha thalassaemia mental retardation, X-linked (ATRX) protein is a 
chromatin remodeling protein that is a homolog of the radiation mutant 54 
(Rad54) translocase (Stayton et al., 1994). The ATRX gene is located on the 
long-arm of the X-chromosome (Xq13.3), and contains 36 exons spanning over 
300 kilobases (kb) of genomic DNA (Gibbons et al., 1995; Picketts et al., 1996a). 
Analysis of the ATRX gene revealed that it encodes at least three alternative 
transcripts. Two of the transcripts are the result of an alternative splicing event of 
exon 6, resulting in two 10.5 kb mRNA transcripts that are predicted to give rise 
to slightly different proteins of 265 and 280 (kilodalton) kDa, respectively. The 
third transcript results from a failure to splice out intron 11 of the ATRX gene, 
resulting in a truncated isoform of the ATRX protein (ATRXt) (Bérubé et al., 2000; 
Garrick et al., 2004). The function of the ATRXt protein has not been fully 
elucidated, however it has been found to have binding affinity for the full-length 
ATRX protein suggesting that it may be required to regulate ATRX activity at 
heterochromatin (Garrick et al., 2004; Bérubé et al., 2005). The full-length ATRX 
protein contains two highly conserved domains; a carboxy (C)-terminal 
helicase/adenosine    triphosphatase   (ATPase)   domain    that   is    a   member  
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Figure 1. The ATRX protein structure and function 
A) Representation of the ATRX protein containing two-highly conserved domains 
(the ADD DNA binding domain and the Snf2 chromatin remodeling domain), as 
well as the areas of the ATRX protein that interact with Daxx, MeCP2 and PML 
nuclear bodies. B) Representation of the ATRX protein function at 
pericentromeric heterochromatin. The ADD domain interacts with DNA through 
recognition of the H3K9me3 and H3K4me0 epigenetic modifications (Dhayalan et 
al., 2011; Eustermann et al., 2011; Iwase et al., 2011). ATRX interacts with 
DAXX to allow incorporation of H3.3 into nucleosomes of chromatin (Drané et al., 
2010; Goldberg et al., 2010; Lewis et al., 2010; Wong et al., 2010). 
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of the sucrose non-fermenting 2 (Snf2) family of proteins, as well as an amino 
(N)-terminal ATRX-DNMT3-DNMT3L (ADD) domain containing a plant 
homeodomain (PHD)-like zinc finger, and a C2-C2 GATA-like zinc finger domain  
(Figure 1A) (Picketts et al., 1998; Xie et al., 1999; Aapola et al., 2000; Argentaro 
et al., 2007). On the other hand, the ATRXt protein lacks the C-terminal Snf2 
ATPase domain, but retains the N-terminal ADD domain suggesting it may act 
primarily at pericentromeric heterochromatin (Bérubé, 2011). 
ATRX is a member of the Snf2 subgroup of the switch/sucrose non-fermenting 
(SWI/SNF) family of proteins as it contains seven highly conserved collinear 
domains of this family, demonstrating its function in ATPase chromatin 
remodeling activity (Picketts et al., 1996). SWI/SNF proteins have been shown to 
play roles in a vast array of cellular functions including transcriptional elongation, 
DNA repair, and regulation of mitosis (Carlson and Laurent, 1994; Eisen et al., 
1995; Picketts et al., 1996). 
The ATRX protein also contains an ADD chromatin-binding domain. It has been 
found that ATRX can recognize and bind histone tails through various 
modifications, including trimethylation on lysine 9 of histone 3 (H3K9me3) and 
H3K4me0 (Dhayalan et al., 2011; Eustermann et al., 2011; Iwase et al., 2011). In 
addition, in vitro studies have also shown ATRX has the ability to bind to lysine 4 
of the histone 3 variant, H3.3 (Wong et al., 2010).  
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1.1.2 Cellular functions of ATRX 
ATRX is a nuclear protein crucial for the regulation of the epigenetic environment 
of heterochromatin, mitosis, and gene transcription. It has been established that 
ATRX is required for the proper expression of a subset of genes known as 
ancestral pseudoautosomal region (aPAR) genes (Levy et al., 2008). It was 
determined that ATRX promotes the expression of aPAR genes through the 
incorporation of H3.3 (Levy et al., 2014). ATRX facilitates the incorporation of 
H3.3 into nucleosomes of aPAR gene bodies resulting in the relaxation of barrier 
structures known as G-quadraplexes. Inhibition of G-quadraplex formation allows 
for elongation of RNA polymerase II along the gene body, thus initiating 
transcription (Levy et al., 2014). In the absence of ATRX, H3.3 incorporation into 
nucleosomes of aPAR gene bodies was diminished, thus allowing for the 
formation of G-quadraplexes. These G-quadraplex structures were found to 
block, and subsequently stall RNA polymerase II from progressing along the 
gene body resulting in a significant decrease of aPAR gene expression (Levy et 
al., 2014). These findings reveal a primary role for ATRX in the regulation of 
gene expression. 
ATRX has been shown to influence gene expression through its interaction with 
several factors, including methyl-CpG-binding protein 2 (MeCP2), CCCTC-
binding factor (CTCF), and cohesin. Studies have shown that ATRX binds with 
MeCP2, CTCF, and cohesin to influence the expression of the H19/Igf2 and 
Gtl2/Dlk1 imprinted regions in the postnatal brain. It was determined that MeCP2 
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acts as a recruiter for ATRX binding at these sites, as loss of ATRX does not 
alter the MeCP2 binding efficiency (Kernohan et al., 2010). On the contrary, 
ATRX loss causes a decrease in CTCF and cohesin occupancy at these sites, 
resulting in altered expression of H19, Igf2, and many other imprinted genes 
(Kernohan et al., 2010). In addition, ATRX and MeCP2 binding influences gene 
expression by regulating the chromatin architecture at imprinting control regions. 
It was found that binding of ATRX to chromatin through its interaction with 
MeCP2, repositions nucleosome placement allowing CTCF binding to these sites 
(Kernohan et al., 2014). CTCF binding was found to enable the long-distance 
recruitment of enhancer elements to imprinting control regions through its 
interaction with cohesin, resulting in an increase in expression of imprinted genes 
(Kernohan et al., 2014). 
ATRX has also been found to interact with death domain-associated protein 
(Daxx) to influence gene expression (Xue et al., 2003; Tang et al., 2004). It has 
been shown that the ATRX/Daxx complex exhibits translocase activity, as well as 
mononucleosome-dependent ATPase activity (Xue et al., 2003; Tang et al., 
2004); however, this activity was found not to reposition nucleosomes to 
influence gene expression, suggesting that the ATRX/Daxx complex regulates 
gene expression through an alternative mechanism. Daxx has been discovered 
to act as a chaperone for the H3.3 histone variant. Recent studies demonstrate 
that ATRX forms a chromatin remodeling complex with Daxx to deposit H3.3 at 
both pericentromeric heterochromatin, and telomeres (Figure 1B) (Drané et al., 
2010; Goldberg et al., 2010; Lewis et al., 2010; Wong et al., 2010). It was 
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determined that when ATRX is lost, H3.3 is no longer deposited in nucleosomes 
at pericentromeric heterochromatin and telomeres, leading to decreased levels of 
pericentromeric transcripts, and increased levels of telomeric transcripts in 
embryonic stem cells (Wong et al., 2010). 
In addition to influencing gene expression and the epigenetic environment of 
chromatin, ATRX has also been implicated in the regulation of mitosis. Initially, it 
was determined that ATRX becomes hyperphosphorylated during mitosis 
suggesting that it may be required for proper cell-division (Bérubé et al., 2000). In 
vitro studies have shown that human cells deficient for ATRX, display an irregular 
assembly of chromosomes at the metaphase plate, disruption of spindle 
morphology, and a delay in cell-cycle progression resulting in irregular nuclei 
morphology (Ritchie et al., 2008). In addition, mice lacking ATRX exhibited an 
increase in the abundance of micronuclei in the ventricular zone of the forebrain 
coinciding with previous in vitro findings.   
These studies show that ATRX is required for multiple cellular functions, and loss 
of ATRX can lead to severe detriments during development. 
 
1.1.3 ATR-X syndrome 
ATR-X syndrome (OMIM#301040) is a neurodevelopmental disorder that is 
characterized by a wide range of phenotypic aberrations such as severe 
cognitive deficits, seizures, microcephaly, various developmental abnormalities, 
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and alpha thalassaemia (a decrease of α-globin abundance in the blood) 
(Gibbons et al., 1995; Gibbons and Higgs, 2000; Gibbons, 2006). ATR-X 
syndrome patients have been shown to display intellectual disability associated 
with a profound mental retardation (95% of patients), genital abnormalities (80%), 
skeletal abnormalities (90%), microcephaly (reduction in brain size) (75%), 
seizures (30%), HbH inclusions (87%), and characteristic facial features (94%) 
(Gibbons, 2006). Recent magnetic resonance imaging (MRI) studies have also 
revealed that ATR-X syndrome patients display varying degrees of white matter 
abnormalities, and delayed myelination (Wada et al., 2013). 
ATR-X syndrome results from hypomorphic mutations within the ATRX gene, 
resulting in protein dysfunction. The majority of mutations in the non-truncated 
form of ATRX resulting in ATR-X syndrome, occur in the ADD DNA binding 
domain (49% of cases), and the SWI/SNF2 ATPase chromatin remodeling 
domain (30% of cases) (Gibbons et al., 2008). It has been postulated that 
mutations within the remaining domains of the ATRX protein act as neutral 
polymorphisms rather than lethal mutations (Mitson et al., 2011). 
Mutations within the Snf2 ATPase domain were found to result in defective DNA 
translocase and ATPase activity, as well as abnormal localization of ATRX to 
promyelocytic leukaemia nuclear bodies (PML-NB) (Bérubé et al., 2008; Mitson 
et al., 2011). Furthermore, missense mutations within the ADD domain result in a 
significant decrease of DNA binding ability, and abnormal targeting to 
pericentromeric heterochromatin (Argentaro et al., 2007). These findings indicate 
that ATRX has a subnuclear function in maintaining proper brain development. 
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ATR-X syndrome is an extremely rare disorder, as approximately only 200 
people (prevalence of <1-9/1,000,000) have been diagnosed worldwide 
(Gibbons, 2006). However, it is estimated that the prevalence of ATR-X may 
actually be closer to 1/30-40,000 as some patients have yet to be diagnosed 
(Wada et al., 2013). ATR-X syndrome primarily affects males, as the ATRX gene 
is located on the X-chromosome. Females carrying a mutated ATRX allele are 
phenotyically normal as their cells undergo the phenomenon of non-random X-
inactivation (Gibbons et al., 1992). 
In addition to ATR-X syndrome, mutations within the ATRX gene have been 
implicated in several other neurological disorders such as Juberg-Mar-sidi, X-
linked mental retardation with spastic paraplegia, Carpenter-Waziri, Holmes-
Gang, Smith-Fineman-Myers, and Chudley-Lowry syndromes (Villard et al., 
1996; Abidi et al., 1999; Lossi et al., 1999; Stevenson et al., 2000; Villard et al., 
2000; Abidi et al., 2005) 
ATRX has been implicated to be crucial for proper brain development, as 
mutations within the ATRX gene result in a severe neurological disorder. 
Therefore, it is imperative to study the ATRX protein to further our knowledge of 
its subcellular function in brain development. By increasing our knowledge of the 
ATRX protein, therapies can be devised to combat the neurological disorders 
that stem from mutations within ATRX. 
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1.1.4 Phenotypic abnormalities associated with ATRX  
  loss  
As mentioned above, ATR-X syndrome patients display a series of 
developmental abnormalities, and it has been found that a number of these 
abnormalities are also illustrated in mice deficient for ATRX. To study the 
phenotypic changes in mice when ATRX is lost, Bérubé and colleagues 
developed a mouse model that lacks Atrx expression specifically from the 
forebrain beginning at embryonic day 8.5 (E8.5) (Bérubé et al., 2005).  
Analysis of the prenatal mouse brain revealed that loss of ATRX results in a 
reduction of overall brain size. This was found to be due to hypocellularity in both 
the cerebral cortex and hippocampus that results from a dramatic increase in the 
number of apoptotic cells (Bérubé et al., 2005). It was further determined that the 
increase in apoptosis is not the only mechanism that contributes to a reduction in 
brain size when ATRX is lost. Seah and colleagues utilized a mouse model 
where both ATRX and the tumour suppressing factor p53 were absent (Seah et 
al., 2008). Analysis of newborn mice lacking both ATRX and p53 expression, 
displayed decreased brain size compared to littermate matched controls (Seah et 
al., 2008), suggesting that ATRX functions within multiple mechanisms to 
regulate proper brain development.  
It has recently been reported that ATRX is also required in neural progenitor cell 
(NPC) development and maintenance. Loss of ATRX from the mouse forebrain 
was found to negatively affect cortical layer development in the cerebral cortex. 
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Layer VI of the cortex was found to be inflated, whereas layers II-IV were found 
to be reduced with the loss of ATRX (Ritchie et al., 2014). This abnormality in 
cortical development was determined to be the result of premature cell-cycle exit 
of NPCs as well as a depletion of apical progenitor cells during the initial stages 
of neurogenesis (Ritchie et al., 2014). Taken together, these results highlight the 
importance for proper ATRX function during the early stages of brain 
development.  
In addition to brain development defects, mice lacking ATRX also display 
additional developmental abnormalities. Mice deficient for Atrx were found to 
have a shortened lifespan (approximately 23 days on average), and it was 
resolved that this mortality rate was not due to starvation (Watson et al., 2013). 
Total body weight, and body length were significantly reduced in ATRX-null mice 
when compared to their control counterparts. In addition, these mice also 
displayed kyphosis (abnormal curvature of the spine), decreased bone mineral 
density, loss of trabecular bone, and decreased cortical bone thickness (Watson 
et al., 2013). Watson and colleagues determined that Atrx-deficient mice also 
display a number of endocrine defects. It was determined that levels of the 
insulin-like growth factor 1 (IGF-1) as well as circulating thyroxine (T4) levels 
were significantly reduced in ATRX-null mice (Watson et al., 2013).  
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1.2 Myelination 
1.2.1 The myelin sheath 
The myelin sheath is a specialized and modified plasma membrane that 
encompasses axons of neurons in higher-order vertebrates. Emerging 
approximately 400 million years ago in cartilaginous fish, the myelin sheath 
allows for increased propagation of action potentials along nerve fibres, as well 
as providing trophic support and protection to the axonal cell body (Baumann and 
Pham-Dinh, 2001; Zalc et al., 2008). It has been said that myelination of neurons 
accelerates nerve conduction 20-100 fold then compared to unmyelinated fibres 
(Nave and Werner, 2014). Myelinated segments are separated by unmyelinated 
openings known as the nodes of Ranvier; the location on the axonal membrane 
where sodium/potassium ion (Na+/K+) exchange occurs. When an electrical 
current is generated, it travels along the axonal membrane where it maintains its 
excitatory state due to depolarization at the nodes of Ranvier. Depolarization at 
these nodes, gives the impression that the electrical signal is jumping from node 
to node, a sensation known as saltatory conduction. Limiting the abundance of 
sodium channels as well as extending the distance between channels, 
significantly reduces the amount of ATP required, thus saving the amount of 
energy needed to propagate action potentials (Wang et al., 2008). Interestingly, 
the thickness of the myelin sheath is directly proportional to the thickness of the 
axon; therefore the thicker the axon, the thicker the myelin sheath needs to be to 
allow for proper firing of action potentials (Baumann and Pham-Dinh, 2001). 
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1.2.2 Oligodendrocyte development 
In the central nervous system (CNS) the myelin sheath is generated by 
oligodendrocytes (OLs), whereas the myelin sheath in the peripheral nervous 
system (PNS) is generated by Schwann cells.  
OLs are a subpopulation of glial cell that are responsible for myelinating axons in 
the CNS. Mature myelinating OLs arise due to the differentiation of OL precursor 
cells (OPCs) (Figure 2). Multipotential NPCs are directed to become OPCs 
through several extrinsic factors. Ventrally derived sonic hedgehog (SHH) was 
found to influence NPC specification by binding to the Notch-1 receptor on the 
NPC surface thereby activating the co-receptor Smoothened, which then induces 
oligodendrocyte transcription factor 2 (Olig2) and NK6 homeobox protein (Nkx6) 
expression (Pringle et al., 1996; Orentas et al., 1999). Induction of these two 
factors leads to the first appearance of OPCs in the telencephalon.  
In addition to SHH signaling, it has been reported that fibroblast growth factor 2 
(FGF2) signaling has an independent role in the transition of NPCs into OPCs 
(Chandran et al., 2003; Naruse et al., 2006). It was determined that FGF2 
stimulates either FGF receptor 1 or 2 (FGFR1 or FGFR2), which then activates 
the extracellular signal-regulated kinase 1 and 2 (ERK1 and ERK2) (Chandran et 
al., 2003; Furusho et al., 2011). Phosphorylation of ERK1 and ERK2 
subsequently blocks SMAD signaling, causing the activation of the OL-lineage 
marker Olig2 (Bilican et al., 2008).  
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Figure 2. The oligodendrocyte development pathway 
Oligodendrcoyte precursor cells (OPCs) arise in the subventricular zone of the 
mouse brain from the medial ganglionic eminence, lateral ganglionic eminence, 
and the cerebral cortex beginning at E11.5, E15, and at birth respectively 
(Kessaris et al., 2006). OPCs then migrate to their targeted axon where they then 
undergo a wave of differentiation into postmitotic immature oligodendrocytes, 
which then mature into myelinating oligodendrocytes (Rowitch, 2004). 
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OPCs initially arise in the subventricular zone of the cortex, where they undergo 
a wave of proliferation, followed by subsequent migration to their targeted axon 
(Kessaris et al., 2006; Richardson et al., 2006). OPCs are identified by the 
expression of platelet derived growth factor, alpha (PDGFRα), and NG2, a 
protein encoded by chondroitin sulfate proteoglycan 4 (Cspg4). Both the cell-
surface receptor PDGFRα, and the proteoglycan NG2 are important in 
maintaining the proliferative state of OPCs (Nishiyama et al., 1996; Soriano, 
1997). OPC proliferation requires PDGFRα expression, as it is the receptor for 
the potent PDGFA mitogen (Soriano, 1997). In addition to PDGFA, it has been 
determined that IGF-1 may also be a factor associated with OPC proliferation. 
IGF-1 regulates OPC proliferation by activating the PI3K/Akt pathway via the 
IGF-1 receptor (IGF-1R). Activation of the PI3K/Akt pathway promotes the 
expression and survival of cyclin-D1, a known factor important in cell-cycle 
progression (Pang et al., 2007; Zeger et al., 2007; Bibollet-Bahena and Almazan, 
2009; Romanelli et al., 2009). 
Migration of OPCs to their targeted axons relies on various mechanisms 
including motogenic factors, and cell adhesion molecules. PDGFA and FGF-2 
are two of the most important motogenic factors that influence OPC migration. 
PDGFA affects OPC migration by activating the phosphorylated version of the 
Wasp Veprolin-homologous protein 2 (WAVE2) family of migratory proteins 
through the Fyn, and cyclin-dependent kinase 5 (Cdk5) pathways (Miyamoto et 
al., 2008). On the other hand, FGF-2 independently promotes migration through 
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its recognition and stimulation of FGFR1 on OPCs (Bansal et al., 1996; 
Osterhout et al., 1997; Bribián et al., 2006). 
Cell adhesion molecules also play a vital role in promoting migration of OPCs to 
their targeted axon. As OPCs migrate throughout the extracellular matrix (ECM), 
they come into contact with various molecules that further aid their movement. It 
has been shown that molecules such as laminin, fibronectin, merosin, tenascin-
C, and anosmin-1 are all pro-migratory factors that assist OPC progression 
throughout the forebrain during development (reviewed in Mitew et al., 2014).  
OPCs require several mechanisms acting in unison to properly migrate 
throughout the forebrain and through the ECM to reach their targeted axon. Upon 
reaching their final destination, OPCs undergo terminal differentiation into 
postmitotic immature premyelinating OLs (iOLs) (Rowitch, 2004). 
Differentiation of OPCs into iOLs requires several intrinsic and extrinsic factors 
that act to promote differentiation. It has been shown that OL-specific factors 
such as achaete-scute homolog 1 (Ascl1) and NK2 homeobox protein 2  (Nkx2.2) 
are critical for OPC differentiation, as loss of these factors results in a substantial 
decrease in the number of differentiated iOLs present in the forebrain (Qi et al., 
2001; Sugimori et al., 2008). Furthermore, OLIG2 has been found to activate 
genes that are required for OPC differentiation. OLIG2 regulates this process by 
promoting binding of the BRM/SWI2-related gene 1 (BRG1) chromatin 
remodeling protein to the regulatory regions of genes known to be required for 
OPC differentiation including SRY-box 10 (Sox10), and zinc finger homebox 1b 
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(Zfhx1b) (Yu et al., 2013). Several additional regulators that positively influence 
OPC differentiation have been discovered including triiodothyronine (T3). Studies 
have shown that the abundance of postmitotic iOLs is severely diminished when 
T3 levels are reduced, resulting in severe hypomyelination (Mitew et al., 2014). 
Although the influence of T3 in the promotion of OPC differentiation is well 
known, the exact mechanisms influencing differentiation remain unclear. 
There are several factors that negatively influence differentiation of OPCs as 
well. A long known inhibitor of OPC differentiation is the leucine-rich 
immunoglobulin domain-containing, 1 (LINGO-1) (Mi et al., 2004; 2005). LINGO-
1 negatively regulates OPC differentiation through two independent mechanisms. 
First, LINGO-1 negatively regulates the Fyn kinase signaling pathway, which 
consequently upregulates RhoA signaling which has been found to reduce 
differentiation capacity (Mi et al., 2005). In addition, LINGO-1 also binds to OPC-
specific LINGO-1, which has been shown to negatively regulate OPC 
differentiation (Jepson et al., 2012). An additional well-known inhibitor of OPC 
differentiation is the G-protein coupled receptor 17 (GPCR17). It has been shown 
that overexpression of GPCR17 significantly reduces the differentiation capacity 
of OPCs by increasing the expression of inhibitor of DNA-binding protein 2 and 4 
(ID2 and ID4) proteins (Chen et al., 2009); two known factors in the promotion of 
cell-cycle progression (Iavarone et al., 1994). Conversely, depletion of GPCR17 
has been shown to promote premature differentiation, thus displaying the 
relevance of GPCR17 function during OL-development (Chen et al., 2009). 
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Myelination of neurons requires maturation of immature premyelinating OLs into 
myelinating OLs. Initially, OLs extend membranous processes that contact 
axonal cell bodies resulting in the initiation of myelination. These membranous 
processes, also known as filopodia, are abundant in microfilament fibres. Several 
axonal signaling molecules such as laminin-α2 promote the extension of these 
processes (Morissette and Carbonetto, 1995; Colognato et al., 2002). Binding of 
laminin-α2 to the OL-specific β-1 receptor promotes the dephosphorylation of the 
Fyn tyrosine kinase leading to the activation of integrin-linked kinase (ILK), 
particularly interesting new cysteine-histidine-rich protein (PINCH), and α-parvin. 
Activation of these factors allows for the initiation of actin polymerization and 
consequently, filopodia extension (Hu et al., 2009). 
Inhibitory factors of myelination initiation have also been well studied. 
Polysialylated neural cell adhesion molecule (PSA-NCAM), as well as Jagged-1 
signaling through the Notch-1 receptor are well known factors that inhibit OL 
process extension and contact to the axonal cell body (Wang et al., 1998; 
Charles et al., 2000). In addition, LINGO-1 binding to the Nogo receptor on OLs 
also negatively regulates myelination as it reduces the extension abilities of OL 
filopodia (Mi et al., 2004; 2005).  
After the initial contact of the cytoplasmic membranous processes to the 
unmyelinated axon, the generation of the growing myelin sheath requires several 
myelin-specific factors that act to maintain sheath stability, compaction, and 
thickness. The regulatory mechanisms of myelin-specific gene expression have 
yet to be completely identified; however, there are several transcription factors 
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that have been found to be important for myelin-specific gene expression and 
consequently, myelin sheath formation and maintenance. 
One such factor that has been found to regulate myelin-specific gene expression 
is myelin regulatory factor (MRF). MRF was first identified as a transcriptional 
regulator of myelin-specific gene expression by Emery and colleagues (Emery et 
al., 2009). MRF is a nuclear protein that contains a DNA binding domain 
homologous to the Ndt80 yeast transcription factor, and is expressed exclusively 
in postmitotic OLs (Cahoy et al., 2008; Emery et al., 2009). Emery and 
colleagues determined that loss of MRF from OLs results in a dramatic decrease 
in the expression of several myelin-specific proteins including myelin basic 
protein (MBP), proteolipid protein (PLP), myelin-associated glycoprotein (MAG), 
and myelin oligodendrocyte glycoprotein (MOG) (Emery et al., 2009). On the 
other hand, induced expression of MRF in cultured OPCs stimulated the 
premature expression of these proteins leading to premature myelin formation, 
suggesting that MRF is directly regulating the expression of these genes (Emery 
et al., 2009). In addition, MRF has been noted to be important for myelin sheath 
maintenance, as ablation of MRF from myelinating OLs in 8-week-old mice 
correlated with severe demyelination (Koenning et al., 2012). Interestingly, Mrf 
expression was found to be directly regulated by the OL-specific factor SOX10 as 
it binds to an intronic enhancer in the Mrf transcript (Hornig et al., 2013). MRF 
has been found to be a potential master regulator of myelin-specific gene 
expression; however, the exact mechanism of MRF has yet to be elucidated. 
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In addition to MRF, a transcription factor found to be important in myelin-specific 
gene expression is the putative transcription factor zinc finger protein 191 
(ZFP191). It was determined that loss of ZFP191 results in a severe 
hypomyelination phenotype in the postnatal day 14 (P14) mouse brain (Howng et 
al., 2010). Transmission electron microscopy analysis of extracted spinal cord, 
revealed that ZFP191 mutants displayed a global reduction of myelin correlating 
with the significant reduction in myelin-specific protein expression (Howng et al., 
2010). Interestingly, it was determined that loss of ZFP191 did not affect OPC 
production, proliferation, or differentiation into premyelinating OLs suggesting 
that it is only required for iOL maturation and myelination initiation. Furthermore, 
Howng and colleagues determined that ZFP191 also acts in an OL cell-
autonomous manner to regulate myelin-specific genes, similar to MRF (Howng et 
al., 2010). It is strongly suggested that additional regulatory factors are required 
in the molecular network that controls the expression of myelinating factors; 
however, the majority of these factors have yet to be identified. 
    
1.2.3 Composition of the myelin sheath 
The myelin sheath is a complex, lipid-rich membrane that is assembled and 
maintained by the intricate interaction of proteins and lipids. It has been 
established that in the CNS, 15-30% of the dry weight of myelin consists of 
myelin-specific proteins, and 70-85% consists of lipids (Baumann and Pham-
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Dinh, 2001; Quarles, 2005). Interestingly, this proportion of protein to lipids is 
unique and specific to myelin. 
 
1.2.3.1 Myelin-specific proteins 
Two of the most prominent and vital proteins present within the myelin sheath are 
MBP and PLP. The MBP protein consists of several different isoforms that are 
the result of an alternative splicing event of the Mbp gene. Mbp is located on 
chromosome 18 in both the mouse and human genome, consisting of seven 
exons and spanning 32 kb and 45 kb respectively (Roach et al., 1983; Saxe et 
al., 1985; Sparkes et al., 1987; Gogate et al., 1994). Two of the most prevalent 
isoforms (approximately 95%) of MBP are the 14 and 18.5 kDa isoforms in mice, 
and the 17.2 and 18.5 kDa isoforms in humans (Staugaitis et al., 1990). 
MBP is a crucial factor in myelination as it is required for the formation, 
stabilization, and maintenance of the multilameller structure of myelin 
(Campagnoni and Skoff, 2001). MBP is involved in the tight compaction of the 
myelin sheath as it found between, and pulls together two negatively charged 
surfaces of the lipid membrane forming the major dense line of the myelin sheath 
(Harauz et al., 2009; Min et al., 2009; Aggarwal et al., 2013). It has been found 
that mice lacking MBP display significant myelin abnormalities. Mice lacking MBP 
display severe dysfunction in the compaction of the myelin sheath, demonstrating 
the necessity of MBP in myelin sheath stability and functionality (Privat et al., 
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1979; Roach et al., 1985). MBP is essential in proper brain development as it is a 
limiting factor in CNS myelination. 
In addition to MBP, PLP is also a known factor that is vital to the compaction and 
stabilization of the myelin sheath. PLP is a 20 kDa protein that is encoded by 
Plp1, a small (15 kb) gene located on the X-chromosome. PLP is a tetraspan 
protein that contains four hydrophobic α-helices that span the lipid bilayer 
(Weimbs and Stoffel, 1992). Interestingly, the N-terminus and C-terminus of PLP 
are found on the cytoplasmic sides of the lipid bilayer, which acts to stabilize the 
myelin sheath (Weimbs and Stoffel, 1992; Boison et al., 1995). It has been 
shown that mice lacking PLP, display severe axonal damage due to severe 
hypomyelination (Quarles and Macklin, 2005). PLP is not only an important factor 
for the stabilization and maintenance of the myelin sheath, but it is also crucial for 
providing protection to the axonal cell body. Together, MBP and PLP constitute 
80% of the total proteins in myelin sheath composition (Baumann and Pham-
Dinh, 2001). MBP and PLP are the two most prevalent proteins found in the 
myelin sheath; however there are additional proteins that are vital for proper 
myelination in the CNS, such as MAG, and MOG.  
MAG is a cell-adhesion glycoprotein that is located on the periaxonal glial 
membrane of the myelin sheath. Biochemical analysis of the MAG protein shows 
it has high homology to neural cell-adhesion molecule (NCAM) (Lai et al., 1987). 
Due to its location as well as its homology to NCAM, it has been postulated that 
MAG may be an important factor in myelin sheath initiation. This theory is 
strengthened as loss of MAG has been shown to disrupt glial-axonal contact in 
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mice (Li et al., 1998). In addition, in vivo mouse studies have shown that CNS 
myelination is delayed in the absence of MAG (Montag et al., 1994; Bartsch et 
al., 1997). These studies strongly support the notion that MAG is important in 
myelin sheath development. Although the exact function of MAG is still being 
debated, it has been noted to also be important for OL differentiation, as well as 
myelin sheath maintenance and survival (Quarles, 2007).  
MOG is a transmembrane glycoprotein that is found on the outermost surface of 
the myelin sheath (Pham-Dinh et al., 1993). MOG has been found to be involved 
in the completion and maintenance of the myelin sheath, as well as being 
important for cell-cell communication and mediation of homophilic cell-cell 
adhesion (Roth et al., 1995; Baumann and Pham-Dinh, 2001; Clements et al., 
2003). 
 
1.2.3.2 Lipid content of the myelin sheath 
In addition to myelin-specific proteins, the CNS myelin sheath is composed of a 
high content of lipids. It has been found that the myelin sheath is comprised of 
cholesterol, phospholipids, galactolipids, and plasmologens at a ratio of 2:2:1:1 
respectively (Norton and Poduslo, 1973). Cholesterol is a major constituent of the 
myelin sheath as it constitutes approximately 26% of the dry weight of myelin 
(Norton and Cammer, 1984).  Previous studies have found that cholesterol in 
CNS myelin is synthesized locally and is independent of cholesterol levels in 
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circulation (Jurevics and Morell, 1995). The myelin sheath in the CNS displays an 
unusually high content of cholesterol, as it is 2-fold more abundant in CNS myelin 
compared to any other plasma membrane. The high level of cholesterol affects 
myelin compartmentalization and intracellular trafficking by influencing 
membrane thickness and fluidity (Nave and Werner, 2014). Previous in vivo 
studies have shown that, OLs that cannot synthesize cholesterol display a delay 
in myelin production, signifying that cholesterol biosynthesis is a rate-limiting step 
in CNS myelination (Saher et al., 2005).  
 
1.2.4 Pathologies related to myelin sheath dysfunction 
There are several known neurodegenerative, neurodevelopmental, and 
neuropsychological disorders associated with defects in myelination. The most 
familiar disorder associated with myelin sheath dysfunction is multiple sclerosis 
(MS). MS is a neurodegenerative disorder that is the result of demyelination and 
axonal degeneration. The mechanistic origin of MS remains controversial, as 
both environmental factors and viral infection have been determined to promote 
disease onset (Ascherio and Munger, 2007; Compston and Coles, 2008). 
Although the origin of MS remains debatable, the disease phenotype is 
characterized by the formation of sclerotic plaques. Sclerotic plaque formation 
results in severe inflammation causing demyelination, OL death, astrocytosis, 
and subsequent axonal degeneration (reviewed in Compston and Coles, 2008). 
Although, the myelin sheath is able to partially regenerate, it is unable to maintain 
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its overall integrity, thus leading to permanent demyelination and axonal 
degeneration. Degradation of axons due to demyelination in MS patients have 
been found to lead to severe cognitive defects, tremors, reduced visual acuity, 
spasticity, and over weakness of the body eventually leading to premature death 
(reviewed in Compston and Coles, 2008). To date, therapies addressing MS 
focus on targeting the immune system to suppress the advancement of 
demyelination of neurons rather than focusing on the mechanisms to induce 
remyelination (Nave and Werner, 2014). In addition to MS, myelination 
dysfunction has been characterized in several leukodystrophies, as well as 
schizophrenia. Leukodystrophies are a family of disorders that arise due to 
specific genetic mutations resulting in demyelination of CNS axons.  
Pelizaeus-Merzbacher disease (PMD) is a member of the leukodystrophy family 
that results from mutations within the Plp1 gene causing abnormal levels of the 
PLP protein (OMIM#312080). Resulting mutations in Plp1 cause severe 
demyelination in multiple areas of the brain including the cerebral cortex and 
cerebellum (Seitelberger, 1995). Boys affected with PMD display a severe 
deterioration in intellectual function, impaired movement, ataxia, and spasticity 
(Inoue, 2005). Current therapies for PMD patients target treatment for seizures 
and spasticity, in addition with physical therapy (Xia and Wang, 2013); however, 
therapies focusing on targeting the molecular mechanisms of PMD have yet to 
manifest.  
An additional and rare leukodystrophy that is well known is Krabbe disease (KD). 
KD is the result of mutations in the gene that codes for the lysosomal enzyme 
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galactocerebrosidase (GALC) (OMIM#245200). Abnormal GALC levels results in 
a failure to breakdown galactosylceramide and psychosine leading to the 
degeneration of the myelin sheath (Suzuki, 2003a; 2003b). Current treatments 
include introduction of chemical chaperones to reactivate defective enzymes 
(Berardi et al., 2014); however, no cure has been found. 
Recent studies have shown that myelination defects may also be a contributing 
factor to the disease pathology in individuals with schizophrenia. It was 
determined that several schizophrenic patients displayed a disruption in both 
oligodendrocytes and myelination (reviewed in Haroutunian et al., 2014). 
Furthermore, expression of genes involved in oligodendrocyte development and 
myelination was altered in extracted tissue from deceased schizophrenic 
patients. Genetic alterations resulting in myelination defects, coincide with 
several neurological and behavioural symptoms seen in individuals with 
schizophrenia (reviewed in Haroutunian et al., 2014). Experimental procedures 
performed on animal models of schizophrenia, revealed that moderate changes 
in OL-associated genes resulted in behaviors similar to that seen in human 
schizophrenic patients (Gregg et al., 2009), suggesting that abnormal OL 
development and myelination may be a cause, or result of schizophrenia.  
Abnormal OL development and myelination is associated with several 
neurodevelopmental, neurodegenerative, and neuropsychological disorders; 
however, the exact mechanisms involved have yet to be fully elucidated, thus 
restricting the identification of new, improved, and less invasive therapies for 
these disorders. 
28 
 
1.3 Hypothesis and thesis objectives 
It has been recently discovered that in addition to the severe developmental 
abnormalities, ATR-X syndrome patients also display moderate to severe 
myelination defects that correlate with diminished cognition (Wada et al., 2013). 
As ATRX has been implicated in the regulation of the epigenetic environment of 
heterochromatin, and gene expression; 
I hypothesize that the ATRX chromatin remodeling protein is required for 
proper myelin formation in the CNS by regulating the expression of myelin-
specific genes.  
To test this hypothesis, I set out to: (1) determine if myelination is disrupted in the 
absence of ATRX from the mouse forebrain, (2) determine at what stage in the 
oligodendrocyte development pathway ATRX is required to initiate myelination, 
and (3) determine if ATRX has an oligodendrocyte-specific mechanism in CNS 
myelination. 
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Figure 3. Hypothetical mechanism of ATRX in myelination of neurons 
within the CNS 
I hypothesize that ATRX directly regulates the expression of myelin-specific 
genes within oligodendrocytes that code for proteins that are required for 
oligodendrocyte process extension, myelin sheath initiation, as well as myelin 
sheath compaction and stabilization 
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2 Materials and Methods 
 
2.1 Animal husbandry, tissue harvesting, and genotyping 
All mice were housed in clear cages at 22±1°C and subjected to a 12/12 hour 
light/dark cycle. All mice were fed a standard diet (Harlan Laboratories) and a 
water bottle was placed in each cage so water was available ad libitum. All mice 
were housed, bred, euthanized, and tissues harvested in a facility designed to 
maintain mice. 
In this study, multiple mouse lines were used. Female mice harbouring loxP sites 
flanking exon 18 of the Atrx gene (Atrxf/f) were kindly provided by Dr. Douglas 
Higgs (Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, 
Oxford, United Kingdom). Deletion of exon 18 from the Atrx gene results in a 
truncated and unstable mRNA transcript, thus becoming vulnerable to 
degradation and ultimately eradicating the presence of the ATRX protein. 
Recombination of exon 18 from the Atrx gene mirrors the effect of an ATRX-null 
mutation (Bérubé et al., 2005).  
Heterozygous female mice containing loxP sites flanking exon 18 of the Atrx 
gene (Atrxf/wt) were crossed with male mice that have Cre recombinase inserted 
into the forkhead box G1 (FoxG1) locus, thus allowing for the complete loss of 
Atrx expression specifically from the forebrain beginning at E8.5. Male progeny 
resulting from this cross will be used to assess the role of  
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Figure 4. Schematic of mice harbouring loxP sites used for Cre-loxP 
recombination. 
The top schematic represents the wild-type allele with normal Atrx expression. 
The second schematic represents the allele that has loxP sites flanking exon 18 
of the Atrx gene. The third schematic represents the result of recombination 
using Cre-loxP technology resulting in complete loss of exon 18 of the Atrx gene. 
The white bars represent exons of the Atrx gene, and the black triangles 
represent loxP sites located in the Atrx gene.  
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ATRX in the mouse forebrain, as female mice heterozygous for Atrx expression 
are phenotypically normal. Male mice that have Atrx knocked out from the 
forebrain (AtrxFoxG1Cre) were used as experimental mice, and male mice that 
express Cre recombinase but do not contain loxP sites flanking exon 18 of the 
Atrx gene were used as control mice.  
An additional mouse line was utilized to determine if ATRX has an OL-specific 
role in myelination development. Male mice that have Cre recombinase inserted 
into the 2’, 3’-cyclic-nucleotide 3’-phosphodiesterase (Cnp) locus were generated 
by Dr. Klaus-Armin Nave (Max Planck Institute for Experimental Medicine, 
Göttingen, Germany) (Lappe-Siefke et al., 2003), and generously provided by Dr. 
Brian Popko (University of Chicago, Chicago, Illinois, U.S.A) with the permission 
from Dr. Nave. These male mice were mated with heterozygous female mice 
containing loxP sites flanking exon 18 of the Atrx gene (Atrxf/wt). The resulting 
male progeny (AtrxCnpCre) from this cross lack ATRX specifically from the OL cell-
lineage beginning at E11.5 (Lappe-Siefke et al., 2003).  
To determine the genotypes of our mice, genomic DNA was extracted from tail 
clips/ear notches from each mouse by incubating these samples in a solution of 
100µL of DirectPCR and 5µL of proteinase K (ThermoScientific) for 12 hours at 
55°C. PCR was then performed using primers designed to amplify the Atrx, Cre, 
and Sry genes under the following conditions: Step 1. Initial denaturation - 95°C 
for 3 minutes, Step 2. Denaturation - 95°C for 30 seconds, Step 3. Annealing - 
55°C for 30 seconds, Step 4. Elongation - 72°C for 1:30 minutes (Note: Steps 2-4 
were performed for 35 cycles), followed by Step 5. 72°C for 5 minutes. Primer 
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designs can be located in Table 1. Following PCR amplification, each sample 
was then ran on a 1.5% agarose gel for separation, and then imaged using the 
BioRad Universal Imaging hood (BioRad). 
The mice chosen for either quantitative real-time PCR (qRT-PCR) or western blot 
analysis were euthanized using carbon dioxide (CO2) inhalation followed by 
cervical dislocation. The mice chosen for immunohistological analyses were 
euthanized using CO2 inhalation, and fixed by cardiac perfusion. Cardiac 
perfusion was performed by first injecting 10mL of 1x phosphate buffered saline 
(PBS), followed by injection of a 30mL solution of 4% paraformaldehyde (PFA). 
Following cardiac perfusion, whole mouse brains were harvested and placed in a 
15mL conical tube containing 10mL of 4% PFA. Post-fixation of whole mouse 
brains was carried out for 12 hours at 4°C. Once post-fixation was complete, 
whole mouse brains were then transferred to a solution of 30% sucrose diluted in 
1xPBS for cryoprotection. Following cryoprotection, whole mouse brains were 
embedded in OCT (optical cutting temperature) media and flash frozen using 
liquid nitrogen. Brain tissues were then stored in a -80°C freezer until further use. 
 
2.2 Microarray analysis 
To assess gene expression changes between AtrxFoxG1Cre and control mouse 
brains at both postnatal day 0.5 (P0.5) and P17, a gene expression microarray 
was performed by a member of the laboratory, Dr. Michael Levy (unpublished). 
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RNA was extracted from the forebrain of three pairs of P0.5 AtrxFoxG1Cre and 
control mice, as well as three pairs of P17 AtrxFoxG1Cre and control mice using the 
RNeasy Mini Kit (QIAGEN). Total RNA was then sent to the London Regional 
Genomics Centre (LRGC) for microarray analysis. First, cDNA was synthesized 
using SuperScriptII (Invitrogen) and oligo (dT24) primers. Biotin-labeled cRNA 
was then prepared by cDNA in vitro transcription using the BioArray High-Yield 
RNA Transcript Labeling kit (Enzo Biochem) to incorporate biotinylated UTP and 
CTP. Biotinylated labeled cRNA was then hybridized to an Affymetrix Mouse 
Genome 430 2.0 array chip for 16 hours at 45°C and 60rpm. One microarray chip 
per mouse was used. GeneChips were stained with streptavidin-phycoerythrin 
(SAPE), followed by an antibody solution and a second SAPE solution, with all 
liquid handling performed by a GeneChip Fluidics Station 450.  GeneChips were 
scanned with the Affymetrix GeneChip Scanner 3000 7G (Affymetrix) where the 
GCOS1.4 program was used to generate probe level (.CEL file) data.  
Probe level data was then transferred into the Partek Genomic Suite program 
(Partek), and the RMA algorithm (Irizarry et al., 2003) was used to summarize 
each probe signal, and output the data as probe intensity levels. Summarizing 
the probe signal utilizing the RMA algorithm consists of, binning the data to 
reduce the variation within each group, background correction, and normalization 
of the data from each array chip to each other. Once the probe intensity levels 
have been determined, a one-way ANOVA was used to calculate the p-values for 
each probe set. Furthermore, gene expression fold-changes in AtrxFoxG1Cre 
mouse brains compared to control mouse brains were calculated using the 
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Fisher’s least significant difference model (Tamhane and Dunlop, 2000). Gene 
ontology (GO) analysis of specific gene subsets was performed using the 
Fisher’s exact test (Rhee et al., 2008) in the Partek Genomic Suite program 
(Partek). Heat maps of selected gene targets were generated using respective 
probe intensity levels from both AtrxFoxG1Cre and control mice.  
 
2.3 Quantitative real-time PCR 
Total RNA was isolated from control and knockout mouse forebrains using the 
RNeasy Mini Kit (QIAGEN). Quantity and quality of isolated RNA was then 
measured using the Nanodrop1000 (Thermo Scientific). RNA was then reverse 
transcribed into cDNA using standard PCR settings (65°C for 10 minutes, 
followed by 30°C for 10 minutes, then 42°C for 45 minutes). Confirmation of 
reverse transcription was carried out by PCR using primers designed to the 
internal control, glyceraldehyde 3-phosphate dehydrogenase (Gapdh) (Table 1). 
PCR amplification was performed using standard settings. PCR samples were 
then loaded onto a 1.5% agarose gel and ran at 95V for 22 minutes, and then 
imaged.  
qRT-PCR was carried out to study gene expression changes between 
AtrxFoxG1Cre and control mouse forebrains. First, the online Ensembl genome 
browser 84 database (http://www.ensembl.org/index.html) was used to identify 
optimal gene  
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Table 1. Primer sequences for PCR and qRT-PCR 
Gene Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
Mbp ATCCAAGTACCTGGCCACAG CAGGGAGCCATAATGGGTAG 
Mog AAATGGCAAGGACCAAGATG AAGTGCGATGAGAGTCAGCA 
Mag GCCTGTACCTGGATCTGGAG ATGACCGTGGCTAGGATCTG 
Plp1 GGCCACTGGATTGTGTTTCT GTGGTGTAGAAGCCCTCAGC 
Mobp GAGGAGGACTGGATCTGCTG AGTCCTTGAAGGGGACCTTG 
Cnp GCTGGTTCCTGACCAAAAAG CACCTGGAGGTCTCTTTCCA 
Pdgfrα ACCTCCCACCAGGTCTTTCT GCCAGCTCACTTCACTCTCC 
Cspg4 TCCAGATCACTGGGCCTTAC AGGCGTCTGTCTGTGTCTCA 
Atrx AGAACCGTTAGTGCAGGTTCA 
18 R - TGAACCTGGGGACTTCTTTG 
NeoR - CCACCATGATATTCGGCAAG 
Cre TGACCAGAGATCATCCTTAGCG AATGCTTCTGTCCGTTTGCC 
Sry GCAGGTGGAAAAGCCTTACA AAGCTTTGCTGGTTTTTGGA 
Gapdh CAACGACCCCTTCATTGACCT ATCCACGACCGACACATTGG 
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locations to design DNA primers for PCR amplification. Using the desired gene 
locations, the online Primer3 tool (http://bioinfo.ut.ee/primer3-0.4.0/) was used to 
design optimal DNA primers. Primer sequences for each gene can be found in 
Table 1. qRT-PCR was carried out on 96-well PCR plates. Each well on the 96-
well plate contained a combined solution of cDNA, H2O, the desired primers, and 
iQT,MSYBR® Green Mastermix (BioRad). qRT-PCR was carried out using a 
Chromo-4 thermocycler (BioRad) under standard conditions [Step 1. Initial 
denaturation - 95°C for 3 minutes, Step 2. Denaturation - 95°C for 10 seconds, 
Step 3. Annealing - 55°C for 20 seconds, Step 4. Elongation - 72°C for 30 
seconds (Note: Steps 2-4 were performed for 30-35 cycles), followed by Step 5. 
Final elongation - 72°C for 5 minutes]. A final melting curve was constructed in 
increments of 1°C per plate read. Opticon Monitor 3 sofware (BioRad) was used 
to calculate Ct values for each sample. Ct values for each well were calculated 
automatically after resolving the threshold placement on the amplification curve. 
Ct values were then transferred into the GeneX (BioRad) program to analyze the 
gene expression data. Expression of each gene was calculated from two 
technical replicates and three biological replicates. Gene expression was 
normalized to Gapdh, and an unpaired students t-test was then used to 
determine if expression of each gene was significantly different (p<0.05) between 
control and knockout mice. 
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2.4 Protein isolation  
Total protein was extracted from control and knockout mouse forebrains using 
RIPA lysis buffer (150mM NaCl, 1% NP-40, 50mM Tris, pH 8.0, 0.5% 
deoxycholic acid, 0.1% SDS, 0.2mM PMSF, 0.5mM NaF, 0.1mM Na3VO4, and 1 
protease inhibitor cocktail tablet). 200µL of RIPA buffer was added to a 1.5mL 
PCR tube containing one half of a mouse forebrain. Forebrain tissue was then 
homogenized and put on ice for 20 minutes for cell lysis. Total cell extracts were 
cleared by centrifugation at 10000rpm at 4°C for 20 minutes to pellet cellular 
debris, and then the supernatant containing the soluble cellular fraction was 
collected. Protein quantification was then measured by Bradford assay (Bradford, 
1976). Bradford assay was carried out by first adding 10µL of each sample into a 
96-well plate. 190µL of protein assay dye reagent concentrate (BioRad) was then 
added to each well. 0.5µg/µL, 1µg/µL, 2 µg/µL, 4µg/µL, 6µg/µL, and 8µg/µL of 
bovine serum albumin (BSA) was used a controls. The 96-well plate was then 
loaded into the Wallac Victor2, 1420 multilabel counter machine (Perkin Elmer) 
where the absorbance of each individual sample was recorded. Each sample 
was performed in triplicate, and therefore the average absorbance was used to 
calculate the protein concentration of each sample. An X-Y scatter plot was 
constructed placing the control BSA concentration values on the Y-axis, and the 
corresponding wavelength values on the X-axis. A line of best fit was then 
calculated in excel to determine the equation of the line. The measured 
wavelength of each sample was inputted into this equation to determine their 
subsequent protein concentration.  
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2.5 Western blot analysis 
Western blots were carried out using polyacrylamide gels. Each polyacrylamide 
gel consisted of a 4% stacking gel (780µL ddH2O, 130µL 30% Acrylamide-Bis 
(Bio-Rad), 65µL 2M Tris (pH 6.8), 10µL 10% SDS, 8µL 10% APS, 2µL TEMED 
for a 1mL solution) and a separating gel. In this study, both a 6% separating gel 
(5.9mL ddH2O, 2mL 30% Acrylamide-Bis (Bio-Rad), 2mL 2M Tris (pH 8.8), 
100µL 10% SDS, 30µL 10% APS, 20µL TEMED for a 10mL solution) and a 12% 
separating gel (3.9mL ddH2O, 4mL 30% Acrylamide-Bis (Bio-Rad), 2mL 2M Tris 
(pH 8.8), 100µL 10% SDS, 30µL 10% APS, 20µL TEMED for a 10mL solution) 
were used depending on the size of the desired proteins. A total of 8µL of protein 
ladder (Bio-Rad), and 50ug of protein was loaded into the corresponding wells. 
SDS-PAGE gels were run at 90V for 30 minutes, followed by 130V for 2 hours, in 
1x running buffer. Protein from the gels was then transferred onto a nitrocellulose 
membrane (Pall Life Sciences) at 75V for 2 hours in 1x transfer buffer. 
Nitrocellulose membranes were then placed into a small plastic dish and blocked 
with 5% milk-TBST for 1 hour at room temperature. Following this incubation, the 
desired primary antibody (Table 2) was then diluted in 5mL of 5% milk-TBST and 
added to the dish containing the membrane, and then incubated overnight at 
4°C. The next morning, membranes were place on a rocker where they then 
underwent 4, 10-minute washes with 1x TBST at room temperature. The 
corresponding secondary antibody (Table 3) was then diluted in 5mL of 5% milk-
TBST and added on top of the membrane, and then incubated for 1 hour at room 
temperature. Membranes then underwent another 4, 10-minute washes with   
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Table 2. Primary antibodies used for Western blot analysis and 
immunofluorescence staining 
Protein Antibody Description 
Dilution of 
primary antibody 
Dilution of 
secondary 
antibody 
ATRX (D-5) Anti-mouse, polyclonal (Santa Cruz)  WB – 1:500 WB – 1:4000 
ATRX (H300) Anti-rabbit, polyclonal (Santa Cruz)  IF – 1:100 IF – 1:800 
MBP Anti-rat, monoclonal (Abcam) 
IF – 1:200 
WB – 1:3000 
IF – 1:800 
WB – 1:4000 
MOG Anti-mouse, monoclonal (Millipore)  
IF – 1:200 
WB – 1:3000 
IF – 1:800 
WB – 1:3000 
MAG Anti-mouse, monoclonal (Abcam)  WB – 1:000 WB – 1:4000 
CNPase Anti-mouse, monoclonal (Covance)  WB – 1:3000 WB – 1:4000 
PDGFRα Anti-rabbit, polyclonal (Abcam)  
IF – 1:200 
WB – 1:200 
IF – 1:800 
WB – 1:4000 
APC (CC-1) Anti-mouse, monoclonal (Millipore)  IF – 1:100 IF – 1:800 
OLIG1 Anti-mouse, monoclonal (Santa Cruz)  IF – 1:100 IF – 1:800 
OLIG2 Anti-goat, polyclonal (Santa Cruz)  IF – 1:100 IF – 1:800 
Actin Anti-rabbit, polyclonal (Sigma)  WB – 1:1000 WB – 1:4000 
INCENP Anti-rabbit, polyclonal (Sigma)  WB – 1:10000 WB – 1:10000 
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Table 3. Secondary antibodies used for Western blot analysis and 
immunofluorescence staining 
Secondary antibody and description 
Experimental procedure 
used 
Anti-rat IgG HRP (Santa Cruz) Western blot 
Anti-mouse IgG HRP (Santa Cruz) Western blot 
Anti-rabbit IgG HRP (Santa Cruz) Western blot 
Alexa Fluorophore, goat anti-rabbit IgG 594 nm (Life Technologies) Immunofluorescence 
Alexa Fluorophore, goat anti-rat IgG 488 nm (Life Technologies) Immunofluorescence 
Alexa Fluorophore, goat anti-mouse IgG 594 nm (Life Technologies) Immunofluorescence 
Alexa Fluorophore, goat anti-mouse IgG 594 nm (Life Technologies) Immunofluorescence 
Alexa Fluorophore, donkey anti-goat IgG 594 nm (Life Technologies) Immunofluorescence 
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1xTBST at room temperature. ECL (enhanced chemilluminescence) was then 
added to the membrane for approximately 1 minute. The membrane was then 
exposed onto chemilluminescence film, and then developed with the Konica 
Minolta SRV-101A film developer (Konica Minolta). Protein expression was 
measured by calculating the integrated density of each protein band using 
ImageJ software. Protein expression was normalized to the corresponding 
loading control. INCENP was used as the loading control for proteins that were 
detected using 6% polyacrylamide gels, and Actin was used as the loading 
control for proteins that were detected using 12% polyacrylamide gels. Unpaired 
students t-test was then used to determine if the expression of the protein was 
significantly different (p<0.05) between control and knockout mice. 
 
2.6 Immunofluorescence staining and cell counting 
Embedded whole mouse brains were coronally sectioned (Figure 5) to a 
thickness of 8µm using the Leica CM100 cryostat (Leica Biosystems) and placed 
on glass microscope slides. Slides were then placed in a -80°C freezer until 
further use. 1 hour prior to starting the immunofluorescence protocol, slides 
containing the frozen brain cryosections were taken out of the freezer to allow for 
thawing. Once the samples were completely thawed, slides were placed into a 
1xPBS solution for 5 minutes to allow for sample rehydration. Slides were then 
placed  into  a  slide  holder  containing a  pre-warmed solution of  10mM  sodium  
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Figure 5. Coronal section of the postnatal mouse brain 
Analysis of the postnatal mouse brain was performed by assessing two areas of 
the brain that are rich in white matter and are important for proper cognitive 
function; the corpus callosum and the cerebral cortex (outlined in red boxes). 
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acetate for antigen retrieval.    Antigen   retrieval   was  carried  out  by  slightly  
heating   slides  in  a microwave for 10 minutes. Slides were then taken out, and 
cooled at room temperature for 20 minutes. Slides were then washed once with 
1xPBS, and twice with 1XPBS/0.3% Triton-X. Slides were then placed into a 
staining chamber. Primary antibodies (Table 2) were diluted in a 1xPBS/0.3% 
Triton-X/1% BSA solution, and then 200µL of this solution was added to each 
slide. Slides were incubated overnight at 4°C. The following morning, slides 
underwent 3, 5-minute washes with 1xPBS/0.3%Triton-X. Secondary antibodies 
(Table 3) were diluted in a 1xPBS/0.3% Triton-X/1% BSA solution, and then 
200µL of this solution was added to each slide. Slides were then incubated in the 
dark at room temperature for 1 hour. Following this incubation, slides underwent 
3, 5-minute washes with 1xPBS/0.3%Triton-X. 500µL of DAPI was then added to 
each slide, and incubated for 5 minutes. Slides were then washed twice with 
1xPBS/0.3%Triton-X for 5 minutes each, then washed another two times with 
1xPBS for 5 minutes each. Slides were then coverslipped and prepared for 
microscopy.  
Microscopy for immunofluorescence was carried out using the Leica DMI 6000b 
automated inverted microscope (Leica Biosystems). Images were captured using 
Openlab Software (v5.0 Improvision) and then transferred to the Volocity 
program for further analysis, processing, and cell counting. Using the Volocity 
software, the correct pixel/µm was set and scale bars were positioned onto the 
corresponding image. Cell counts were performed on multiple sections from each 
sample to acquire a global average, and performed on three to four biological 
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replicates. The percentage of cells expressing the protein of interest was 
determined by comparing the number of cells positive for the protein of interest to 
the total number of DAPI-positive cells. An unpaired students t-test was then 
used to determine if the percentage of cells expressing the protein of interest was 
significantly different (p<0.05) between control and knockout mice. 
 
2.7 Analysis of cholesterol abundance 
Cholesterol levels in the forebrains from P14 AtrxFoxG1Cre and control mice were 
measured by the Metabolic Phenotyping Laboratory at Robarts Research 
Institute (Western University, London, Ontario, Canada). Whole mouse-brains 
were isolated from P14 AtrxFoxG1Cre and control mice as described above, and 
flash-frozen in dry ice. Brains were then transported to Brian Sutherland at the 
Metabolic Phenotyping Laboratory for further processing.  
Weights of each brain sample were initially recorded, followed by mincing with a 
scalpel and transferred to a glass tube. Tissue lipids were extracted using the 
Folch extraction method (Folch et al., 1957). First, 2.2mL of methanol was added 
to each tube containing minced brain samples and incubated for 1 hour at room 
temperature, followed by the addition of 4.4mL of chloroform. 
A radioactive tracer was then incorporated into each sample to allow for lipid 
recovery analysis. This was achieved by adding 400µL of a 0.1µCi/mL stock of 
3H-Cholesterol Oleate to each sample. In parallel, 400µL of this isotope was 
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aliquoted, in duplicate, into scintillation vials to allow for counts added 
calculations. Counts added allows us to determine the value of 100% recovery.  
Samples were then mixed with the isotope, and incubated at 4°C for 24-48 hours 
to achieve total lipid extraction. The samples were filtered using Whatman paper 
into a fresh glass tube. The original glass tube was then rinsed with 0.9mL of a 
2:1 ratio of chloroform:methanol, and then filtered through Whatman paper into 
the new glass tubes, followed by the addition of 1.5mL saline and incubated for 
1-2 hours at room temperature. The combination of saline and methanol allows 
for the separation of the chloroform containing the extracted lipids, from the rest 
of the solution. Using a Pasteur pipette, the chloroform fraction was removed and 
then placed into a fresh glass tube and made up to a 10mL solution with 
chloroform.  
To calculate the abundance of cholesterol in each sample, two separate assays 
were performed to assess total cholesterol levels, and free cholesterol levels. 
First, a solution containing a combination of Triolein and cholesterol standard, 
and diluted in isopropanol, was aliquoted in triplicate to calculate a standard 
curve for each assay. Next, 50-200µL of each sample was aliquoted, in duplicate, 
into separate glass tubes. Simultaneously, 0.5mL of each sample was aliquoted 
into scintillation vials containing scintillation fluid, to calculate recovery efficiency. 
Each sample and standard were dried under nitrogen to remove the presence of 
chloroform. 500µL of 1% TritonX-100 was then added to each tube and 
incubated for 1 hour at room temperature, followed by drying under nitrogen. 
50µL deionized water was added to each tube to solubilize the sample, as the 
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assays to assess cholesterol levels cannot be run on chloroform based samples. 
Each sample was then placed into a 37°C water bath 15 minutes prior to running 
each assay.  
To calculate the abundance of total cholesterol and free cholesterol, standard kits 
were used [Wako kits 439-17501, 435-35801 (Wako Diagnostics), respectively]. 
For each assay, 1mL of colour reagent solution (from the corresponding Wako 
kit) was added to each sample and cholesterol standard. These solutions were 
then mixed, and incubated for 15 minutes at 37°C. Follow this incubation, 
samples were cooled down at room temperature for 5 minutes. The absorbance 
of each sample and standard was then measured at a wavelength of 600nm 
using the Beckman DU 640 Spectrophotometer (Beckman Coulter).  
An X-Y scatter plot was constructed placing the cholesterol standard values on 
the Y-axis, and the corresponding absorbance values on the X-axis. A line of 
best fit was then calculated in excel to determine the equation of the line. The 
measured absorbance of each sample was inputted into this equation to 
determine their subsequent concentration. Mean values of total cholesterol and 
free cholesterol from control and AtrxFoxG1Cre samples were calculated, and the 
abundance of cholesterol esters is calculated by subtracting free cholesterol from 
total cholesterol. Unpaired students t-test was then used to determine if 
cholesterol concentrations between control and AtrxFoxG1Cre samples were 
significantly different (p<0.05). 
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3 Results 
3.1 Transcriptional profiling of the postnatal AtrxFoxG1Cre 
forebrain reveals a decrease in myelin-specific gene 
expression  
The ATRX chromatin remodeling protein is a known regulator of gene 
expression; therefore, to examine the gene expression profile in the developing 
mouse forebrain in the absence of ATRX, a microarray was carried out on P17 
AtrxFoxG1Cre and littermate-matched control mouse forebrains. It was determined 
that gene expression was significantly changed in AtrxFoxG1Cre mice compared to 
littermate-matched control mice if the fold-change was upregulated, or 
downregulated by 1.3 fold (p<0.05). Examination of the P17 microarray data 
revealed that ten of the top fifty-downregulated genes in AtrxFoxG1Cre mice are 
genes implicated in oligodendrocyte development and CNS myelination (Figure 
6A). Furthermore, GO analysis of significantly downregulated genes (-1.5 fold; 
p<0.05) revealed that genes involved in various aspects of myelination were of 
the top significantly downregulated genes in the P17 AtrxFoxG1Cre forebrain (Figure 
6C). To determine the total number, and identity of the myelin-specific genes that 
are significantly downregulated in P17 AtrxFoxG1Cre mice, the P17 microarray was 
compared to an RNA-sequencing transcriptome database of glia, neurons, and 
vascular cells of the cerebral cortex (Zhang et al., 2014). Using this database, 
one can determine which genes are expressed, and at what concentration in a 
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specific cell type compared to all other cell types in the cerebral cortex. Here, we 
sought to determine the identity of genes specifically expressed in mature 
myelinating OLs, as these cells are responsible for the development of the myelin 
sheath, and compare this gene set to the significantly downregulated genes from 
the P17 microarray. First, a list depicting genes enriched in myelinating OLs 
compared to all other neuronal cells was constructed using the RNA-sequencing 
database (Zhang et al., 2014). Furthermore, a 4-fold cutoff was set to narrow the 
set of genes that are truly specific to myelinating OLs. This set of genes was then 
compared to significantly downregulated genes (-1.3 fold; p<0.05) from the P17 
microarray to determine how many of those downregulated genes were in fact 
myelin-specific genes. It was determined that 76 myelin-specific genes were 
significantly downregulated in P17 AtrxFoxG1Cre mice compared to their control 
counterparts (Figure 6B).  
Validation of the gene expression changes from the P17 microarray was 
performed by qRT-PCR on cDNA extracted from P20 AtrxFoxG1Cre and control 
forebrain samples. It was determined that expression of several myelin-specific 
genes, was downregulated in P20 AtrxFoxG1Cre mice compared to littermate-
matched controls, thereby confirming the P17 microarray data (Figure 6D). 
Taken together, this data suggests that ATRX may be an important factor for 
proper myelin formation in the mouse brain.   
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Figure 6. Transcriptional profiling of genes from P17 AtrxFoxG1Cre microarray 
revealed a significant decrease in expression of myelin-specific genes 
compared to littermate-matched controls. 
A) Heat-map displaying the top fifty-downregulated genes in P17 AtrxFoxG1Cre 
mice compared to controls. B) Heat-map displaying the top downregulated 
oligodendrocyte-specific genes in P17 AtrxFoxG1Cre mice compared to controls. C) 
GO-analysis of downregulated genes in P17 AtrxFoxG1Cre mice. D) qRT-PCR of 
myelin-specific genes from P20 AtrxFoxG1Cre mice. Expression of each gene was 
normalized to Gapdh. N=2. Error bars represent range of expression for two 
biological replicates. 
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3.2 Loss of ATRX from the mouse forebrain results in 
hypomyelination  
Next, we set out to determine if the decrease in myelin-specific gene expression 
observed in P20 AtrxFoxG1Cre mice, results in a defect in myelin sheath 
development. To address this matter, P20 AtrxFoxG1Cre and littermate-matched 
control mouse brains were processed for western blot analysis and 
immunofluorescence staining. To determine if loss of ATRX has a deleterious 
effect on myelin-specific protein expression, western blot analysis of the myelin-
specific markers CNP, MOG, MBP, and MAG was carried out using protein that 
was isolated from P20 mouse forebrains. It was determined that protein 
expression of CNP, MOG, MBP, and MAG was significantly reduced in P20 
AtrxFoxG1Cre forebrains compared to littermate-matched controls (Figure 7A and 
7B). Additionally, immunofluorescence co-staining of MBP and MOG was carried 
out on whole-brain cryosections from P20 AtrxFoxG1Cre and littermate-matched 
control mice to analyze the abundance and expression pattern of myelin in the 
mouse forebrain.  It was observed that expression of both MBP and MOG was 
significantly decreased in the corpus callosum (a white-matter-rich area of the 
brain) of P20 AtrxFoxG1Cre mice compared to their control counterparts (Figure 
7C).  This finding was also observed in the cerebral cortex, as MBP and MOG 
expression were both significantly reduced and sparser in P20 AtrxFoxG1Cre mice 
compared   to  littermate-matched   control   mice   (Figure 7C).   These   findings  
57 
 
 
 
 
 
 
 
 
Figure 7. Expression of myelin-specific proteins is significantly reduced in 
P20 AtrxFoxG1Cre mice compared to littermate-matched controls.   
A) Western blot of ATRX, INCENP, CNP, MBP, MOG, MAG, and Actin from 
forebrain samples of P20 AtrxFoxG1Cre and control mice.  B) Quantitative analysis 
of western blot. ATRX was normalized to INCENP, whereas CNP, MBP, MOG, 
and MAG were normalized to Actin. N=4. Error bars represent ± standard error of 
the mean (±SEM). *p<0.001. C) Immunofluorescence staining of MBP and MOG 
in P20 AtrxFoxG1Cre and control corpus callosum and cerebral cortex. N=3. Scale 
bar represents 70µm. DAPI stains the nucleus of the cell.  
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illustrate that loss of the ATRX chromatin remodeling protein results in severe 
hypomyelination in the mouse forebrain, and therefore we can conclude that 
ATRX is required for proper myelination in the CNS. 
 
3.3 Hypomyelination in the AtrxFoxG1Cre mouse forebrain is 
not due to a reduction in neuronal cell number 
The hypomyelination phenotype seen in the forebrains of P20 AtrxFoxG1Cre mice 
may be the result of a reduction in the total number of neurons that can be 
myelinated. To address the possibility that the total number of neurons is 
decreased in P20 AtrxFoxG1Cre mice, immunofluorescence staining of the neuron-
specific marker neuronal nuclei antigen (NeuN) was carried out on whole-brain 
cryosections of P20 AtrxFoxG1Cre and control mice. Co-staining of P20 AtrxFoxG1Cre 
and control mouse brain cryosections for DAPI and NeuN allowed us to 
determine the percentage of neurons in the mouse forebrain. Counts of DAPI-
positive cells revealed that the total number of cells in a set area is equal 
between P20 AtrxFoxG1Cre and control mice (Figure 8A and 8B). Furthermore, it 
was determined that approximately 76% of DAPI-positive cells are neurons in 
P20 control mouse forebrains, and this percentage of neurons was found to be 
equivalent in the P20 AtrxFoxG1Cre mouse forebrain (Figure 8A and 8C). As 
neuronal cell number is unchanged between P20 AtrxFoxG1Cre and litter-matched 
control  mice,  we  can  deduce  that  the  hypomyelination  phenotype  observed  
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Figure 8. Hypomyelination is not due to a reduction in the number of 
neurons in the mouse brain. 
A) Immunofluorescence staining of NeuN and ATRX in the cerebral cortex of P20 
AtrxFoxG1Cre and control mice. N=3. Scale bar represents 70µm. B) Cell counts 
were performed to analyze the total number of DAPI-positive cells per unit area. 
C) Cell counts were performed to analyze the percentage of NeuN-positive cells 
compared to DAPI-positive cells. N=3. Error bars represent ±SEM. p>0.05. DAPI 
stains the nucleus of the cell.  
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in AtrxFoxG1Cre mice is not due to a reduction in the number of neurons, but due to 
a defect in the initiation of myelination by OLs.  
 
3.4 Oligodendrocyte precursor cell production is unchanged 
in AtrxFoxG1Cre mice at birth 
Onset of myelination may be impeded by multiple factors including deficiencies in 
OPC production, proliferation, and/or differentiation into postmitotic immature 
OLs. We first wanted to assess OPC production and morphology in AtrxFoxG1Cre 
mice at birth. Microarray analysis performed on P0.5 mouse forebrain samples 
revealed that expression of two known OPC markers, Pdgfrα and Cspg4 [1.16 
fold (p>0.05) and -1.11 fold (p>0.05) respectively], was unchanged in P0.5 
AtrxFoxG1Cre mice compared to littermate-matched controls. To confirm that the 
expression of these OPC markers is unchanged when ATRX is absent, qRT-
PCR was carried out on cDNA from P0.5 AtrxFoxG1Cre and littermate-matched 
control mouse forebrains.  It was determined that expression of both Pdgfrα and 
Cspg4 was unchanged in P0.5 AtrxFoxG1Cre mice compared to controls (Figure 
9A). To determine if this effect is observed at the protein level, western blot -
analysis and immunofluorescence staining of the OPC marker PDGFRα, was 
performed. Western blot analysis revealed that protein expression of PDGFRα 
was unchanged between P0.5 AtrxFoxG1Cre and littermate-matched control mice 
(Figure 9B and 9C).  OPC   production   was   further   examined   by  performing  
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Figure 9. Expression of OPC markers is unchanged in P0.5 AtrxFoxG1Cre mice 
compared to littermate-matched controls. 
A) qRT-PCR of Atrx, Pdgfrα, and Cspg4 from P0.5 AtrxFoxG1Cre mice. Expression 
of each gene was normalized to Gapdh. N=3. Error bars represent ±SEM. 
*p<0.001 for Atrx. p>0.05 for Pdgfrα, and Cspg4. B) Western blot of ATRX, 
PDGFRα, and INCENP from forebrains of P0.5 AtrxFoxG1Cre and control mice. C) 
Quantitative analysis of western blot. ATRX, and PDGFRα was normalized to 
INCENP.  N=4. Error bars represent ±SEM. p>0.05. D) Immunofluorescence 
staining of PDGFRα in the cerebral cortex of P0.5 control and AtrxFoxG1Cre mice. 
Scale bar represents 70µm. DAPI stains the nucleus of the cell E) Quantitative 
analysis of the percentage of PDGFRα-positive cells compared to total number of 
DAPI-positive cells. N=3. Error bars represent ±SEM. p>0.05  
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immunofluorescence staining for PDGFRα on P0.5 whole-brain cryosections. To 
assess OPC production capability in P0.5 AtrxFoxG1Cre mice compared their 
control counterparts, cell counts for PDGFRα-positive cells were performed in the 
cerebral cortex, as the majority of OPCs populating the brain at birth arise from 
the cerebral cortex (Kessaris et al., 2006). It was determined that the percentage 
of OPCs in the cerebral cortex was similar between P0.5 AtrxFoxG1Cre and 
littermate-matched control mice (Figure 9D and 9E). These findings infer that 
ATRX loss from the forebrain does not affect OPC production/maintenance, and 
therefore must have an alternative role in myelin sheath formation. 
 
3.5 Differentiation of oligodendrocyte precursor cells into 
immature oligodendrocytes is hindered in the absence 
of ATRX 
A potential mechanism that ATRX may have in the myelination process is the 
regulation of OPC differentiation into premyelinating iOLs. To study this 
possibility, immunofluorescence staining of APC and OLIG2 was carried out on 
whole-brain cryosections from P10 AtrxFoxG1Cre and littermate-matched control 
mice. It was determined that the number of APC/OLIG2-positive cells was 
significantly reduced in the corpus callosum of P10 AtrxFoxG1Cre mice compared to 
littermate-matched   control   mice   (Figure 10A and 10B).   These   data     
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Figure 10. The number of APC/OLIG2-postive cells is significantly 
decreased in P10 AtrxFoxG1Cre mice compared to littermate-matched 
controls.  
A) Immunofluorescence staining of APC and OLIG2 in the corpus callosum of 
P10 AtrxFoxG1Cre and control mice. B) Cell counts were performed to determine 
the percentage of APC/OLIG2-positive cells per DAPI-positive cells. N=3. Scale 
bar represents 100µm. Error bars represent ±SEM. *p<0.05. DAPI stains the 
nucleus of the cell. 
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strongly suggests that ATRX is required for OPC differentiation into iOLs. 
Although differentiation of OPCs is impeded in the absence of ATRX, the defect 
in differentiation does not fully explain the severe hypomyelination phenotype 
seen in P20 AtrxFoxG1Cre mice; therefore, ATRX must also be required during the 
final stage of myelin sheath development by influencing maturation of iOLs into 
myelinating OLs. 
 
3.6 Cholesterol biosynthesis is unaffected in the P14 
AtrxFoxG1Cre mouse forebrain  
Cholesterol biosynthesis is crucial to myelination as 26% of the myelin sheath is 
composed of cholesterol. Analysis of the P17 microarray revealed that several 
genes involved in cholesterol biosynthesis were downregulated in the P17 
AtrxFoxG1Cre mouse forebrain compared to age-matched controls (data not 
shown). Therefore, we hypothesized that ATRX was required for cholesterol 
biosynthesis, as loss of ATRX may cause a decrease in cholesterol levels and 
consequently cause a delay in myelin formation. To study ATRX and its effects 
on cholesterol biosynthesis, cholesterol levels were measured in 14 day-old mice 
(peak of cholesterol biosynthesis in the mouse brain) in collaboration with Brian 
Sutherland at the Robarts Research Institute. This was accomplished by first, 
isolating lipids from the forebrain, and then using standard kits to quantify total 
cholesterol  as  well  as  free  cholesterol   levels.   Total   cholesterol,  and  free  
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Figure 11. Cholesterol levels are unchanged in the absence of ATRX from 
P14 mice. 
Total cholesterol, free cholesterol, and cholesterol ester levels. N=4. Error bars 
represent ±SEM. p>0.05. 
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cholesterol levels were found to be unchanged in P14 AtrxFoxG1Cre mice compared 
to age-matched controls (Figure 11). Overall, these results suggest that ATRX 
does not influence myelination by regulating cholesterol biosynthesis. 
 
3.7 Generation of a novel mouse model to study the 
oligodendrocyte-specific function of ATRX   
Intricate interaction between several key cell types, such as OLs, astrocytes, and 
neurons is necessary for proper myelin formation; therefore, a disruption in any 
of these cell types can lead to a hypomyelinated phenotype. Because OLs are 
the glial cells that myelinate neurons in the CNS, we wanted to determine if 
ATRX has an OL-specific effect on myelin sheath formation. To study the 
function of ATRX within OLs, transgenic male mice that express Cre 
recombinase under control of the Cnp promoter (Lappe-Siefke et al., 2003) were 
mated with female mice containing loxP sites flanking exon 18 of the Atrx gene 
(Bérubé et al., 2005). This cross results in the deletion of Atrx specifically from 
OLs (referred to as AtrxCnpCre) beginning at approximately P5. It was determined 
that the proportion of oligodendrocytes defined by OLIG1-positive cells, was 
unchanged between P20 AtrxCnpCre and littermate-matched control mice (Figure 
12A and 12B). Immunofluorescence co-staining of OLIG1 and ATRX on 
cryosections  of  P20  AtrxCnpCre   and  littermate-matched  control  mouse  brains  
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Figure 12. ATRX expression is successfully lost from OLs in AtrxCnpCre 
mice.  
A) Immunofluorescence staining of OLIG1 and ATRX in the corpus callosum of 
P20 AtrxCnpCre and control mice. N=3. Scale bar represents 70µm. DAPI stains 
the nucleus of the cell. B) Cells counts that assess the proportion of the number 
of OLIG1-positive cells per DAPI-positive cells per unit area. C) Cell counts that 
assess the proportion of the number of ATRX-positive cells per OLIG1-positive 
cells. Cell counts were performed on an N=2. Errors bars represent the range of 
two biological replicates. 
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confirmed that Atrx was successfully deleted from OLs in AtrxCnpCre mice (Figure 
12A and 12C). These results suggest that this mouse model is a good model to 
study the OL-specific effects of ATRX in myelination. 
 
3.8 Oligodendrocyte-specific deletion of ATRX does not 
 affect myelin formation in the mouse brain 
As ATRX has been shown to directly regulate gene expression, it was 
hypothesized that ATRX may influence CNS myelination by regulating the 
expression of myelin-specific genes in mature myelinating OLs. P20 AtrxCnpCre 
and littermate-matched control mice were utilized to assess the OL-specific 
function of ATRX. 
Characterization of the mouse phenotype was first performed to assess if loss of 
ATRX from OLs results in abnormal physical traits compared to age-matched 
controls. It was determined that P20 AtrxCnpCre and littermate-matched control 
mice appeared proportionally similar to one-another in their overall body length 
(Figure 13A and 13B)  
To determine if loss of ATRX from OLs results in hypomyelination in the mouse 
brain, we performed western blot analysis of the myelin markers MOG, MBP, and 
MAG from protein isolated from whole forebrains of P20 AtrxCnpCre and control 
mice (Figure 14A). It was found that the expression of MOG and MBP was 
unchanged  in  P20  AtrxCnpCre   mice  compared  to  littermate-matched  controls  
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Figure 13. Characterization of the P20 AtrxCnpCre and littermate-matched 
control mouse phenotypes 
A) Images of P20 control and AtrxCnpCre mice. B) Measurements of mouse 
lengths (mm). N=4. Error bars represent ±SEM. p>0.05 
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(Figure 14B). Additionally, this finding was corroborated by immunofluorescence 
co-staining of MBP and MOG on brain cryosections. Immunofluorescence 
staining revealed that expression of MBP and MOG in both the corpus callosum 
and the cerebral cortex was analogous between P20 AtrxCnpCre and littermate-
matched controls (Figure 14C). This finding brings us to the conclusion that the 
abundance of myelin is unchanged in mice that lack ATRX specifically from OLs. 
Taken together, these results strongly suggest that myelin sheath formation does 
not require ATRX within OL cells and therefore does not directly regulate myelin-
specific gene expression. These findings imply that ATRX must be required in a 
different cell type to allow for proper formation of the myelin sheath in the CNS.  
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Figure 14. Expression of myelin-specific proteins is unchanged between 
P20 AtrxCnpCre mice compared to littermate-matched controls.  
A) Western blot of MOG, MBP, and Actin from forebrains of P20 AtrxCnpCre and 
control mice. B) Quantitative analysis of western blot. MBP, and MOG were 
normalized to Actin. N=3. Error bars represent ±SEM. p>0.05. DAPI stains the 
nucleus of the cell. C) Immunofluorescence staining of MBP and MOG in the 
corpus callosum and cerebral cortex of P20 AtrxCnpCre and control mice. N=3. 
Scale bar represents 70µm. 
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4 Discussion 
 
4.1 Summary of results 
The ATRX chromatin remodeling protein has been found to be an essential factor 
for proper brain development, as mutations within the human ATRX gene result 
in ATR-X syndrome. ATR-X is a neurodevelopmental disorder characterized by 
cognitive defects, seizures, and microcephaly (Gibbons, 2006). Furthermore, 
recent MRI studies revealed that ATR-X syndrome patients also display varying 
degrees of white matter abnormalities, and delayed myelination (Wada et al., 
2013). Studies have implicated ATRX in several cellular processes including 
regulation of the epigenetic environment of heterochromatin, mitosis, and gene 
expression. The present study identifies not only a novel function of ATRX, but 
also an additional regulator of myelination within the mouse CNS. 
To assess the changes in gene expression when ATRX is lost from P17 mouse 
forebrains, a microarray was carried out. Transcriptional profiling of the 
microarray revealed that expression of several myelin-specific genes was 
significantly downregulated in P17 AtrxFoxG1Cre mouse forebrains compared to 
age-matched controls. In addition, GO-analysis of significantly downregulated 
genes in the forebrain of P17 AtrxFoxG1Cre mice revealed that genes involved in 
several processes of myelination were of the most significantly downregulated 
genes. To determine if the reduction of myelin-specific gene expression in the 
AtrxFoxG1Cre forebrain correlated with a decrease in myelin formation, we analyzed 
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the forebrains of AtrxFoxG1Cre and littermate-matched control mice at postnatal day 
20, as the majority of neurons have been fully myelinated by this time. It was 
determined that loss of ATRX from the P20 forebrain results in significant 
hypomyelination in both the cerebral cortex and corpus callosum; two areas of 
the brain that are highly abundant in white matter and crucial for proper cognition. 
Therefore, we can conclude that ATRX is in fact required for proper myelination 
within the CNS. 
Hypomyelination in the brain can be the result of numerous consequences, 
including a reduction in the total number of axons that can potentially be 
myelinated. It was resolved that neuronal cell numbers were equivalent between 
P20 AtrxFoxG1Cre and control samples, implying that the observed hypomyelination 
phenotype in the P20 AtrxFoxG1Cre forebrain is due to a defect in myelin 
development and not to due a reduction in the number of myelinated neurons.  
I next wanted to determine the mechanism by which ATRX acts to allow for 
myelin formation to take place. I first analyzed the production and morphology of 
OPCs at P0.5, as a decrease in the number of OPCs or malfunction of OPCs 
would result in a myelination defect. It was established that OPC production and 
morphology is unaffected in the absence of ATRX, suggesting that ATRX is 
required further downstream in the OL-development pathway. A possible 
mechanism of ATRX in myelin sheath formation is its potential requirement for 
OPC differentiation into premyelinating iOLs. It was determined that loss of ATRX 
from the P10 AtrxFoxG1Cre mouse forebrain results in a decrease in the number of 
premyelinating iOLs. A defect in OPC differentiation can result in a decrease in 
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myelination as it limits the number of OLs that can myelinate axons; however, the 
decrease in the number of immature OLs when ATRX is absent, does not 
correlate with the severe hypomyelination phenotype observed in the P20 
AtrxFoxG1Cre mouse forebrains. Therefore is it postulated that ATRX is required not 
only for OPC differentiation into iOLs, but is also required for the maturation of 
iOLs into myelinating OLs.  
The myelin sheath is a modified plasma membrane that is enriched with 
cholesterol. Cholesterol is a major constituent of the myelin sheath (~26% of the 
dry weight of myelin), and previous studies have shown that mice with OLs that 
cannot synthesize cholesterol, display a delay in myelin sheath production 
(Norton and Cammer, 1984; Saher et al., 2005). This led us to hypothesize that 
proper myelin sheath formation may be influenced by ATRX through the 
regulation of cholesterol synthesis.   
Cholesterol levels were assessed at P14 as this time point represents the peak 
of myelination in mice. It was determined that the abundance of total cholesterol, 
free cholesterol, and cholesterol esters was analogous between P14 AtrxFoxG1Cre 
and control mouse forebrains. In addition, it was determined that the abundance 
of total cholesterol was similar to that of free cholesterol, and the presence of 
cholesterol esters was negligible. Cholesterol present in the brain is synthesized 
internally; therefore, the cholesterol found within the brain consists strictly of free 
cholesterol with no presence cholesterol esters (Baumann and Pham-Dinh, 2001; 
Quarles, 2005). These findings allow us to conclude that ATRX does not regulate 
CNS myelin sheath formation by influencing cholesterol biosynthesis.  
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The myelin sheath in the CNS is generated by a subset of glial cells known as 
OLs. Regulation of myelin-specific gene expression within OLs is still poorly 
understood. In recent years, one such factor has emerged as a potential “master 
regulator” of myelin-specific gene expression. MRF is a transcriptional regulator 
that has been found to be crucial for myelin sheath formation. Ablation of MRF 
from OLs impedes myelin sheath formation almost completely; however, 
induction of MRF in OPCs can promote premature myelination (Emery et al., 
2009).  
As ATRX has been implicated in the regulation of gene expression, I 
hypothesized that ATRX may act in a similar fashion to MRF, and act as a direct 
transcriptional regulator of several myelin-specific genes that are required for 
myelin sheath formation. To address this question, I first developed a novel 
mouse model in which Atrx is completely eradicated specifically from OL-lineage 
cells (AtrxCnpCre). To our surprise, analysis of both the cerebral cortex and corpus 
callosum revealed that myelination occurred normally in P20 mice lacking ATRX 
specifically from OLs; suggesting that ATRX does not directly regulate myelin-
specific gene expression in OLs. 
Taken together, these results allow for the rejection of my hypothesis. These 
findings illustrate that ATRX is required for myelin sheath formation in the CNS 
by not only regulating OPC differentiation, but also by influencing the maturation 
of iOLs into myelinating OLs, and does so through an OL non cell-autonomous 
mechanism. 
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4.2 ATRX acts in a non cell-autonomous role to regulate 
 myelin sheath formation 
Initiation of myelin sheath formation requires numerous intracellular and 
extracellular mechanisms to act synergistically to allow for proper ensheathment 
of axons. Myelination in the central nervous system requires precise interaction 
of several cell types, including OLs, astrocytes, microglia, and neurons. It was 
hypothesized that ATRX may regulate the expression of myelin-specific genes 
within OLs, as these cells are the subtype of glial cell that myelinate axons; 
however, it was determined that myelination occurs normally when ATRX is lost 
from OLs, suggesting that ATRX must be required within in different cell 
population to promote myelination. 
 
4.2.1 ATRX may act to control neuronal-specific gene  
  expression to regulate myelin sheath formation 
Myelination is complex and tightly regulated process that is influenced not only 
by OL-intrinsic factors, but by axonal activity, secreted ligands, and expression of 
axonal surface ligands as well (Emery, 2010). Preliminary findings from our lab 
suggest that ATRX may have a neuronal-specific function in the regulation of 
myelination.  
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Female mice containing loxP sites flanking exon 18 of the Atrx gene were mated 
with male transgenic male mice that express Cre recombinase under control of 
the neuronal-specific marker, calcium/calmodulin-dependent protein kinase II 
(CamkII) promoter (Chen et al., 2001). The resulting male progeny (AtrxCamkIICre) 
from this cross lacks ATRX specifically from postmitotic neurons. Co-
immunofluorescence staining for ATRX and NeuN demonstrated that at P20, 
ATRX has yet to be lost from postmitotic neurons in AtrxCamkIICre mice (Appendix 
A); therefore, these mice cannot be used to study a potential neuronal-specific 
function of ATRX on myelin sheath formation. Conversely, it was determined that 
by 8-weeks of age, ATRX has been successfully lost from neurons in AtrxCamkIICre 
mice (Appendix A), and therefore can be used to study the neuronal-specific 
effect of ATRX on myelin sheath maintenance at a later age.  
Preliminary evidence suggests that myelin sheath maintenance is disrupted in 
AtrxCamkIICre mice at 3-months of age, as expression of myelin-specific markers 
were found to be significantly reduced in AtrxCamkIICre mice compared to controls 
when analyzed by western blot and immunofluorescence staining (Appendix B). 
These preliminary findings suggest that ATRX has a neuronal-specific effect on 
myelin sheath maintenance, and therefore may have a neuronal-specific effect 
on myelin sheath formation; however, further experimentation will need to be 
carried out to resolve this theory.  
ATRX may therefore regulate expression of genes that code for secreted factors 
and/or neuronal-specific factors that function by promoting OPC differentiation 
into iOLs, as well as maturation of iOLs into myelinating OLs. It has been found 
86 
 
that OPC differentiation into premyelinating iOLs relies on signaling molecules 
from the targeted axonal cell body. One such mechanism is the Notch-1 signaling 
pathway that is activated through binding of secreted axonal molecule 
F3/contactin (Hu et al., 2003). The Notch-1 signaling pathway can both positively 
and negatively regulate OPC differentiation.  Axonally derived F3/contactin binds 
the Notch-1 receptor on OPCs, and promotes OPC differentiation. This is 
achieved as F3/contactin binding to Notch-1 promotes the binding of downstream 
cytoplasmic target Deltex-1 (DTX-1) to the Notch intracellular domain (NICD) 
protein. This binding causes cleavage of NICD which allows it to translocate into 
the nucleus, where it then positively regulates the expression of a selection of 
myelin-specific genes, and thus OPC differentiation into immature premyelinating 
OLs (Hu et al., 2003). On the other hand, the Notch-1 signaling pathway can 
inhibit differentiation, as Jagged-1 binding to Notch-1 inhibits OPC differentiation 
by activating Hes1 and Hes5 expression (Wang et al., 1998; Kondo and Raff, 
2000). 
In addition to the promoting the differentiation of OPCs, axonal signaling 
molecules have also been implicated in initiating the onset of myelination. One 
such molecule that has been shown to promote myelination is laminin-α2 
(Morissette and Carbonetto, 1995; Colognato et al., 2002). Laminin-α2 binds the 
OL-specific β-1 receptor, thus promoting the dephosphorylation of the Fyn 
tyrosine kinase. This dephosphorylation event results in the activation of ILK, 
PINCH, and α-parvin leading to the polymerization of actin filaments, resulting in 
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the extension of the OL filopodia and allowing contact initialization with 
unmyelinated axons (Liang et al., 2004; Bauer et al., 2009; Hu et al., 2009). 
A gene expression microarray was performed to assess the expression changes 
between P0.5 AtrxFoxG1Cre and control mice as well as P17 AtrxFoxG1Cre and control 
mice. Analysis of these microarrays revealed that expression of contactin-1 (also 
known as the F3 neural cell surface protein) was slightly decreased in both P0.5 
and P17 AtrxFoxG1Cre mice [-1.17 fold (p>0.05) and -1.073 (p>0.05) respectively] 
compared to controls. It was also revealed that laminin-α2 was also slightly 
decreased in P17 AtrxFoxG1Cre mice [-1.14 fold (p>0.05)] compared to controls. 
Although the expression changes seen are not significant, validation by qRT-
PCR should be performed to reveal the true expression changes of these genes, 
as microarrays have long been known to have inaccuracies.   
A potential mechanism for ATRX is that it may be required to positively regulate 
the expression of contactin-1 and/or laminin-α2, thus promoting OPC 
differentiation, and/or the maturation of immature OLs into myelinating OLs. 
ATRX may achieve this by directly influencing contactin-1 and laminin-α2 gene 
expression as described previously (Levy et al., 2014), or through its interaction 
with MeCP2, CTCF, or Daxx (Drané et al., 2010; Goldberg et al., 2010; Kernohan 
et al., 2010; Lewis et al., 2010; Wong et al., 2010; Kernohan et al., 2014).  
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4.2.2 Astrocyte influence in CNS myelination  
The majority of studies that examine the mechanisms of CNS myelination have 
focused primarily on the OL-specific effects, as well as the axonal influences that 
promote myelin sheath formation. It has been documented that in addition to OLs 
and neurons, astrocytes are also a key contributor to myelination in the CNS.  
Astrocytes are the most abundant and diverse subpopulation of glial cell found in 
the CNS, and are primarily involved in the organization and maintenance of brain 
structure and function (Sofroniew and Vinters, 2010; Lundgaard et al., 2014). 
Astrocytes have been found to be required for neuronal migration and process 
extension during brain development, as well as being crucial for neuronal survival 
(Powell and Geller, 1999; Wagner et al., 2006). In addition, astrocytes have also 
been found to be required not only for OL-development, but for myelination 
initiation and maintenance as well. 
Astrocytes have been shown to influence OPC differentiation and myelin sheath 
formation through its interactions with OLs and neurons. Recently, it was 
revealed that through two separate mechanisms, OPC differentiation is 
influenced by the release of the promyelinating cytokine, leukemia inhibitory 
factor (LIF) from astrocytes (Fischer et al., 2014). OL and astrocyte co-culture 
experiments determined that the tumor necrosis factor (TNF) derived from OLs, 
activates TNFR2 on astrocytes. Activation of TNFR2 then results in the PI3K-Akt-
dependent secretion of LIF, leading to an increase in expression of myelin-
specific factors (Fischer et al., 2014). In addition, Ishibashi and colleagues further 
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determined that during development, neuronal activity simulates the release of 
ATP, upon which signals neighboring astrocytes to release LIF (Ishibashi et al., 
2006). As ATRX is a known regulator of gene expression, loss of ATRX 
specifically from astrocytes may alter the expression pattern of several of these 
positive and negative regulators, and thereby potentially modifying the 
myelination phenotype. 
It has been shown that loss of ATRX from the mouse forebrain results in an 
increase in the number of reactive astrocytes (McConkey unpublished). This 
increase may result in hypomyelination as it has been found that an increase in 
the number of reactive astrocytes can have detrimental effects in brain 
development. It has been discussed that an increase in reactive astrocytes can 
amplify the production of cytokines leading to an exacerbation of inflammation. In 
addition, reactive astrocytes can increase the release of toxic materials such as 
glutamate and reactive oxygen species (ROS) (Sofroniew and Vinters, 2010; 
Lanciotti et al., 2013). This production and release of toxic substances can result 
in damage to the myelin sheath leading to increased neurodegeneration. 
ATRX has been found to be important for proper NPC proliferation and 
differentiation. Loss of ATRX was found to result in premature NPC differentiation 
leading to an increase in the number of outer radial glia, as well as an increase in 
the generation of postmitotic projection neurons (Ritchie et al., 2014). As radial 
glial cells are multipotent progenitor cells, they have the capability to differentiate 
into various cell types including astrocytes (Vaccarino et al., 2007). It is therefore 
a possibility that premature differentiation of NPCs due to a loss of ATRX, may 
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also result in an increase in the number of reactive astrocytes; however further 
experimentation is required to assess this hypothesis. 
  
4.2.3 Systemic regulation and growth factor influence of  
  myelin sheath formation in the CNS 
CNS myelination is not only regulated by cell-cell communication between OLs 
and neurons as well as between OLs and astrocytes, but is also regulated by the 
IGF-1 growth factor, and systemically by circulating T4.  
T4 and its activated version T3 are tyrosine-based hormones that are produced 
by the follicular cells of the thyroid gland, and have been implicated to be crucial 
factors in proper brain development. It has been established that hypothyroidism 
results in mental retardation and delayed myelination (Dussault and Ruel, 1987); 
two characteristics observed in ATR-X syndrome patients. Thyroid hormones 
have been determined to be crucial for both differentiation and maturation of OLs 
in the CNS. T3 has been found to block OPC proliferation, therefore initiating 
differentiation of OPCs into immature OLs (Baas et al., 1998; Park et al., 2001). 
In addition, hypothyroidism impedes the onset of myelination by delaying the 
expression of several crucial myelin-associated factors, including fatty acid α-
hydroxylase, galactosyltransferase, sialyl-transferase, and sulfotransferase 
(Dussault and Ruel, 1987). Furthermore, thyroid hormones have been found to 
directly regulate the expression of the myelin-specific genes, Mbp and Mag 
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(Farsetti et al., 1991; Rodriguez-Peña et al., 1993). It was observed that induced 
hypothyroidism in mice resulted in decreased MBP mRNA expression, and it was 
further determined that the promoter region of Mbp is susceptible to thyroid 
hormone binding, suggesting that Mbp expression is directly (at least partially) 
regulated by thyroid hormones (Farsetti et al., 1991). These studies reveal that 
thyroid hormones have a fundamental role in the development of the OL pathway 
and the onset of myelination. 
In addition to thyroid hormones, IGF-1 has also been found to be an important 
regulator of CNS myelination. IGF-1 has been established as a significant factor 
in the differentiation, maturation, and survival of OLs (Carson et al., 1993; 
McMorris et al., 1993). Overexpression of IGF-1 in mice, revealed a substantial 
increase in both the number of OLs, and the abundance of myelin (Carson et al., 
1993; Ye et al., 1995). On the other hand, mice lacking IGF-1 display a 
significant reduction in the myelin-specific markers MBP and PLP at 3-weeks of 
age, a characteristic of delayed myelination (Ye et al., 2002). In addition, it was 
revealed that mice lacking the IGF1 receptor (IGF1R) from OLs displayed 
significant reductions in overall brain size, number of OPCs, as well as a 
reduction in the number of differentiated iOLs leading to a decrease in 
myelination (Zeger et al., 2007). These findings strongly demonstrate that the 
IGF-1/IGF1R signaling pathway is crucial for proper OL and myelin sheath 
development. 
It has been previously shown that loss of ATRX from the P20 mouse forebrain 
and anterior pituitary, results in decreased circulating T4 and IGF-1 levels 
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(Watson et al., 2013). In addition, it was also determined that loss of ATRX 
results in decreased expression of the thyroid stimulating hormone (Tsh) 
(Watson et al., 2013). TSH is made by thyrotropes, a population of cells that are 
located in the anterior pituitary, and who directly influence the regulation of T4. 
As these factors are known to be crucial for OL-development and myelination, a 
potential mechanism of ATRX in myelin sheath formation, may be its requirement 
for the transcriptional regulation of these factors through previously seen 
mechanisms (Drané et al., 2010; Goldberg et al., 2010; Lewis et al., 2010; Wong 
et al., 2010; Kernohan et al., 2014; Levy et al., 2014). It is still unclear whether 
the loss of ATRX results in decreased levels of T4 and IGF-1 separately, or if the 
decrease of IGF-1 is the result of T4 dysfunction, as it has been found that T4 
can bind to the Igf-1 transcript and thus can regulate its expression (Wang et al., 
2010). Our group is currently addressing the role of ATRX in the regulation of T4 
and IGF-1, and findings from this study may further elucidate the role of ATRX in 
myelin sheath formation. 
 
4.3 Future Directions 
To address the hypotheses that ATRX may influence OPC differentiation and 
maturation of iOLs through neuronal or astrocyte-specific effects, transgenic 
mouse lines will be utilized to conditionally delete ATRX from postmitotic neurons 
and from astrocytes in the CNS prior to myelin sheath formation.  
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To assess the neuronal-specific function of ATRX, female mice containing loxP 
sites flanking exon 18 of the Atrx gene will be crossed with transgenic male mice 
containing the Cre recombinase gene downstream of the Nex promoter 
(Goebbels et al., 2006). This cross will result in progeny (AtrxNexCre) that will have 
a deletion of Atrx exclusively from postmitotic neurons beginning at 
approximately E12.5 (Goebbels et al., 2006).  
To assess the astrocyte-specific effect of ATRX, a mouse model to conditionally 
deplete ATRX from astrocytes that has been previously characterized will be 
used (McConkey unpublished).  Female mice containing loxP sites flanking exon 
18 of the Atrx gene were crossed with transgenic male mice containing the Cre 
recombinase gene downstream of the glial high affinity glutamate transporter 
(Glast) promoter. This cross results in progeny (AtrxGlastCreERT) that have a 
deletion of Atrx exclusively from astrocytes upon administration of tamoxifen. 
To address the myelination phenotype when ATRX is lost specifically from 
neurons and astrocytes, identical experimental procedures as the ones 
performed in section 3.2 of this thesis, will be carried out. Findings from these 
experiments will allow us to establish if ATRX has a neuronal-specific and/or an 
astrocyte-specific effect on myelin sheath formation in the CNS. 
To identify extracellular factors that may be required for myelin sheath formation, 
mass spectrometry will be performed on isolated cell co-culture media from 
separate OPC/neuronal and OPC/astrocyte cell co-culture experiments, using 
primary cells extracted from AtrxNexCre and control mice, as well as AtrxGlastCreERT 
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and control mice. Mass spectrometry analysis of cultured medium from these 
separate cell co-culture experiments will enable us to identify extracellular 
signaling molecules that are required for myelination, as well as facilitate in the 
detection of secreted molecules that are differentially expressed when ATRX is 
lost from neurons and astrocytes. 
In addition to secreted ligands, expression of intrinsic neuronal-specific and 
astrocyte-specific factors that are essential for myelin sheath formation may also 
be dysregulated in the absence of ATRX. To assess neuronal-specific and 
astrocyte-specific gene expression changes when ATRX is lost from post-mitotic 
neurons, RNA-seq will be carried out on RNA isolated from P5, P14, and P20 
AtrxNexCre and control cortical neurons, as well as RNA isolated from P5, P14, and 
P20 AtrxGlastCreERT and control astrocytes, that have been separated by 
fluorescence-activated cell sorting (FACS). Cells from P5 mice will be used, as 
OPC differentiation is highly active at this time. Cells from P14 mouse forebrains 
will be used, as this time point represents the peak of myelination, and cells from 
P20 mouse forebrains will be used, as the myelin sheath is highly abundant at 
this time. Identification of dysregulated neuronal-specific and astrocyte-specific 
genes, that code for factors implicated in myelination is essential as an ATRX-
dependent process may regulate the expression of these genes.  
Comparative analysis of extracellular signaling ligands by mass spectrometry, 
and analysis of differential gene expression by RNA-seq will allow us to identify 
potential neuronal and astrocyte-specific targets whose expression may be 
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regulated by ATRX. This data will allow us to generate additional hypotheses to 
identify the exact molecular mechanism of ATRX in CNS myelination. 
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Figure 15. Proposed model of ATRX and its potential mechanism in 
myelination of neurons in the mouse CNS 
ATRX may regulate the expression of neuron-specific genes such as 
F3/contactin and/or laminin-α2, to influence oligodendrocyte precursor cell 
differentiation and/or maturation of immature oligodendrocytes into myelinating 
oligodendrocytes respectively (i). ATRX may also act to regulate astrocyte-
specific genes such as leukemia inhibitory factor (LIF) or other astrocyte-specific 
genes (ASG), which would be required for oligodendrocyte precursor cell 
differentiation (ii). An additional mechanism of ATRX is that it may act to regulate 
the expression of thyroid stimulating hormone (Tsh) which then regulates the 
expression of thyroid hormones (TH) and ultimately oligodendrocyte 
development and myelination (iii). 
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5 Conclusions 
The present study addresses a novel role of ATRX in the development of OLs 
and myelin sheath formation in the CNS. It was determined that loss of ATRX 
from the mouse forebrain results in hypomyelination, and that this phenotype is 
due to a defect in OPC differentiation into iOLs, and iOL maturation into 
myelinating OLs. Furthermore, it was resolved that ATRX does not have an OL 
cell-autonomous role in myelination. It is suggested that ATRX influences myelin 
sheath formation and maintenance by potentially regulating the expression of 
neuronal-specific and/or astrocyte-specific factors that are required for 
myelination, as well as potentially regulating circulating T4 and IGF-1 levels 
(Figure 15). Elucidation of the role of ATRX in myelin production would present a 
novel non cell-autonomous mechanism that regulates myelin formation. 
Transcriptional regulation of neuronal-specific and astrocyte-specific genes that 
code for factors that function by instructing OPC differentiation, and OL 
maturation have yet to be fully elucidated; therefore, this discovery would be 
beneficial, as it will further our understanding of the mechanisms involved in 
myelination in the postnatal mouse forebrain. ATRX causes severe cognitive 
deficits, seizures, and microcephaly, all of which are associated with loss of white 
matter. These findings give the prospect of potentially finding a method to 
alleviate hypomyelination defects in ATR-X patients, which may lead to 
discoveries of potential therapies for ATR-X patients, as well as other myelin 
relevant disorders such as multiple sclerosis, various leukodystrophies, and 
neuropsychiatric disorders. 
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Appendices 
 
 
Appendix A. ATRX expression is retained in neurons in P20 AtrxCamkIICre 
mice, but is lost from neurons in 3-month-old AtrxCamkIICre mice  
Immunofluorescence staining of NeuN and ATRX in the cerebral cortex of P20 
and 3-month-old AtrxCamkIICre and control mice. N=1. Scale bar represents 70µm. 
DAPI stains the nucleus of the cell. 
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Appendix B. Expression of myelin-specific proteins is reduced in 3-month-
old AtrxCamkII  mice compared to littermate-matched controls 
A) Western blot of MOG, MBP, and Actin from forebrain samples of 3-month-old 
AtrxCamkIICre and control mice.  B) Quantitative analysis of western blot. MOG and 
MBP were normalized to Actin. N=2. Error bars represent the range of 
expression of two biological replicates. C) Immunofluorescence staining of MBP 
and MOG in P20 AtrxFoxG1Cre and control corpus callosum and cerebral cortex. 
N=1. Scale bar represents 70µm. DAPI stains the nucleus of the cell.  
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